

CARLO TASCINI

RUOLO ATTUALE
*Professore associato*

Informazioni personali

Luogo e data di nascita Marsciano (Pg) 06/07/1963

Cittadinanza Italiana

:Udine, via Nimis, 23/A

🖂: carlo.tascini@uniud.it

**** +39 0432 559353 │+39 348 0623360

Esperienza lavorativa

**a.a. 2022/2023**

**Corso di Laurea in Medicina e chirurgia**

Precorso: MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

4 anno di corso – 37,5 ore – 3 CFU

**Corso di Laurea in Medicina e chirurgia**

Precorso: TIROCINIO DI MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

4 anno di corso – 25 ore – 1 CFU

**Corso di Laurea in Infermieristica – sede di Udine**

Insegnamento: MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

2 anno di corso – 12 ore – 1 CFU

**Corso di Laurea in Infermieristica – sede di Pordenone**

Insegnamento: MALATTIA INFETTIVE

Settore scientifico disciplinare: MED/17

2 anno di corso – 12 ore – 1 CFU

**Scuole di Specializzazione a.a. 2021/2022**

**(Scuole di spec. in Anestesia e Rianimazione, Ematologia, Geriatria, Igiene e medicina preventiva, Malattie**

**infettive e tropicali, Neurologia, Pediatria, Reumatologia)**

Insegnamento: MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

1, 2, 3, 4, 5 anno di corso – 185,4 ore – 30,9 CFU

**(Scuola di spec. in Malattie infettive e tropicali)**

Insegnamento: TIROCINIO DS MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

1, 2, 3, 4 anno di corso – 3000 ore – 100 CFU

**Dottorato di ricerca in Scienze Biomediche e biotecnologiche – 38° ciclo**

Supervisione di dottoranda senza borsa

**a.a. 2021/2022**

**Corso di Laurea in Medicina e chirurgia**

Precorso: MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

4 anno di corso – 37,5 ore – 3 CFU

**Corso di Laurea in Medicina e chirurgia**

Precorso: TIROCINIO DI MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

4 anno di corso – 25 ore – 1 CFU

**Corso di Laurea in Infermieristica – sede di Udine**

Insegnamento: MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

2 anno di corso – 12 ore – 1 CFU

**Corso di Laurea in Infermieristica – sede di Pordenone**

Insegnamento: MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

2 anno di corso – 12 ore – 1 CFU

**Corso di Laurea in Ostetricia**

Insegnamento: MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

2 anno di corso – 12 ore – 1 CFU

**Scuole di Specializzazione a.a. 2020/2021**

**(Scuole di spec. in Anestesia e Rianimazione, Ematologia, Geriatria, Igiene e medicina preventiva, Malattie**

**infettive e tropicali, Neurologia, Pediatria, Reumatologia)**

Insegnamento: MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

1, 2, 3, 4, 5 anno di corso – 173,4 ore – 28,9 CFU

**(Scuola di spec. in Malattie infettive e tropicali)**

Insegnamento: TIROCINIO DS MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

1, 2, 3, 4 anno di corso – 2640 ore – 88 CFU

**a.a. 2020/2021**

**Corso di Laurea in Medicina e chirurgia**

Precorso: MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

4 anno di corso – 37,5 ore – 3 CFU

**Corso di Laurea in Medicina e chirurgia**

Precorso: TIROCINIO DI MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

4 anno di corso – 25 ore – 1 CFU

**Corso di Laurea in Infermieristica – sede di Udine**

Insegnamento: MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

2 anno di corso – 12 ore – 1 CFU

**Corso di Laurea in Infermieristica – sede di Pordenone**

Insegnamento: MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

2 anno di corso – 12 ore – 1 CFU

**Scuole di Specializzazione a.a. 2019/2020**

**(Scuole di spec. in Anestesia e Rianimazione, Ematologia, Geriatria, Igiene e medicina preventiva, Malattie**

**infettive e tropicali, Neurologia, Pediatria, Reumatologia)**

Insegnamento: MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

1, 2, 3, 4, 5 anno di corso – 176,4 ore – 29,4 CFU

**(Scuola di spec. in Malattie infettive e tropicali)**

Insegnamento: TIROCINIO DS MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

1, 2, 3 anno di corso – 2640 ore – 88 CFU

Ai sensi dell’art. 23 della Legge 240/2010, al dott. Carlo Tascini sono stati conferiti i seguenti incarichi

d’insegnamento presso i corsi di studio di questo Dipartimento:

**a.a. 2019/2020**

**Corso di Laurea in Medicina e chirurgia**

Precorso: MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

4 anno di corso – 37,5 ore – 3 CFU

**Corso di Laurea in Medicina e chirurgia**

Precorso: TIROCINIO DI MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

4 anno di corso – 25 ore – 1 CFU

**Corso di Laurea in Infermieristica – sede di Udine**

Insegnamento: MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

2 anno di corso – 12 ore – 1 CFU

**Corso di Laurea in Infermieristica – sede di Pordenone**

Insegnamento: MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

2 anno di corso – 12 ore – 1 CFU

**Corso di Laurea in Ostetricia**

Insegnamento: MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

2 anno di corso – 12 ore – 1 CFU

**Scuole di Specializzazione a.a. 2018/2019**

**(Scuole di spec. in Anestesia e Rianimazione, Ematologia, Igiene e medicina preventiva, Malattie infettive e**

**tropicali, Neurologia, Pediatria)**

Insegnamento: MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

1, 2, 3, 5 anno di corso – 143,4 ore – 23,9 CFU

**(Scuola di spec. in Malattie infettive e tropicali)**

Insegnamento: TIROCINIO DS MALATTIE INFETTIVE

Settore scientifico disciplinare: MED/17

1, 2, 3 anno di corso – 1950 ore – 65 CFU

Istruzione e Formazione

Data 02/03/1989
**Università di Perugia
Titolo conseguito** Diploma di Laurea in Medicina e Chirurgia

Data 28/10/1993
**Università di Perugia
Titolo conseguito** Diploma di Specializzazione in Malattie Infettive

Data 30/10/1997
**Università di Perugia
Titolo conseguito** Diploma di Specializzazione in Microbiologia e Virologia

Data 14/10/2015
**Scuola** Istituto di Management della Scuola Superiore Sant’Anna

**Titolo conseguito** Corso di formazione manageriale per dirigenti di struttura complessa

Capacità e competenze personali

|  |  |
| --- | --- |
| Madrelingua | Italiano |
| Altre lingue | Livello |
| Inglese | Ottimo |
|  |  |
|  |  |

Altro

*Esempio: incarichi accademici*

Pubblicazioni

Elenco delle 194 pubblicazioni edite a stampa reperibili su Scopus e/o Web of Science e/o Pubmed:

1. Tolins JP, Dupont B, Pialoux G, Menichetti F, **Tascini C**, Saag MS, Powderly WG, Cloud GA, Dismukes WE. Amphotericin versus fluconazole in cryptococcal meningitis [2]. NEW ENGL J MED [Internet]. 1992;326(23):1567-9 (IF:**59.558**).
2. Pauluzzi S, Fiorio F, Pasticci MB, Cassano F, De Socio G, **Tascini C**. Infectious fevers of difficult diagnosis in the immunocompetent host. G Mal Infett Parassit [Internet]. 1992;44(12):894-900.
3. Cagini L, Bartoli A, Morelli F, Cirocchi R, Boselli C, Giustozzi G, Pasticci MB, Tascini C, Pierucci P, Stagni G. Emergency laparotomy in AIDS patients. Chirurgia [Internet]. 1993;6(11):731-4.
4. Baldelli F, Moretti MV, Pasticci MB, **Tascini C**, Pauluzzi S. Bacterial pneumonia in immunocompromised patients. G Mal Infett Parassit [Internet]. 1994;46(3-4):178-81.
5. Vecchiarelli A, Monari C, Baldelli F, Pietrella D, Retini C, **Tascini C**, Francisci D, Bistoni F. Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS. J Infect Dis [Internet]. 1995;171(6):1448-54 **(IF: 5.88**).
6. Vecchiarelli A, Retini C, Pietrella D, Monari C, **Tascini C**, Beccari T, Kozel TR. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1β secretion from human monocytes. Infect Immun [Internet]. 1995;63(8):2919-23 (**IF:3.94**).
7. Pasticci MB, Baldelli F, D'Alo F, Moretti A, Piersimoni C, Sbaraglia G, Sposini T, Stagni G, **Tascini C**, Pauluzzi S. Atypical mycobacterium infections in AIDS: Clinical and microbiological features. J Chemother [Internet]. 1995;7(SUPPL. 4):187-9 (**IF: 1,604**).
8. Scavizzi A, Baldelli F, Capparelli G, Merletti L, Pasticci MB, Polidori M, **Tascini C**, Sbaraglia G. In vitro suceptibility of mycobacterial isolates from AIDS patients. J Chemother [Internet]. 1995;7(SUPPL. 4):87-9 (**IF: 1,604**).
9. Retini C, Vecchiarelli A, Pietrella D, Monari C, **Tascini C**, Beccari T, Bistoni F. Modulation of cytokine secretion by cryptococcal polysaccharide from human monocytes. Ig Mod [Internet]. 1995;104(4):683-94.
10. Monari C, Vecchiarelli A, Pietrella D, Perito S, **Tascini C**, Retini C, Bistoni F. Anti-infectious state induced by chronic experimental infection with enterococcus faecium. J Chemother [Internet]. 1995;7(SUPPL. 4):93-5 (**IF: 1,604**).
11. **Tascini C**, Baldelli F, Monari C, Retini C, Pietrella D, Francisci D, Bistoni F, Vecchiarelli A. Inhibition of fungicidal activity of polymorphonuclear leukocytes from HIV-infected patients by interleukin (IL)-4 and IL-10. AIDS [Internet]. 1996;10(5):477-83 (**IF: 2,69**).
12. Vecchiarelli A, Retini C, Monari C, **Tascini C**, Bistoni F, Kozel TR. Purified capsular polysaccharide of *Cryptococcus neoformans* induces interleukin-10 secretion by human monocytes. Infect Immun [Internet]. 1996;64(7):2846-9 (**IF: 3.94**).
13. Retini C, Vecchiarelli A, Monari C, **Tascini C**, Bistoni F, Kozel TR. Capsular polysaccharide of *Cryptococcus neoformans* induces proinflammatory cytokine release by human neutrophils. Infect Immun [Internet]. 1996;64(8):2897-903 (**IF: 3.94**).
14. Iorio AM, Alatri A, Francisci D, Preziosi R, Neri M, Donatelli I, Castrucci MR, Biasio LR, **Tascini C**, Iapoce R, Pierucci P, Baldelli F. Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users. Vaccine [Internet]. 1997;15(1):97-102 (**IF: 3.413**).
15. Monari C, Baldelli F, Pietrella D, Retini C, **Tascini C**, Francisci D, Bistoni F, Vecchiarelli A. Monocyte dysfunction in patients with acquired immunodeficiency syndrome (AIDS) versus *Cryptococcus neoformans*. J Infect [Internet]. 1997;35(3):257-63 (**IF:4.382**).
16. **Carlo Tascini,** Francesco Menichetti, Silvia Bozza, Albano Del Favero and Francesco Bistoni Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii J Antimicrob Chemother 1998; 42: 270–271 (**IF: 2.5**)
17. **Tascini C**, Vecchiarelli A, Preziosi R, Francisci D, Bistoni F, Baldelli F. Granulocyte-macrophage colony-stimulating factor and fluconazole enhance anti-cryptococcal activity of monocytes from AIDS patients. AIDS [Internet]. 1999;13(1):49-55 **(IF: 2.69**).
18. Cardinali G, Martini A, **Tascini C**, Bistoni F, Gerner-Smidt P, Graves LM, Hunter S, Swaminathan B. Critical observations on computerized analysis of banding patterns with commercial software packages [2] (multiple letters). J Clin Microbiol [Internet]. 1999;37(3):876-7 (**IF: 4.068**).
19. **Tascini C**, Menichetti F, Bozza S, Fedele M, Preziosi R, Allegrucci M, Del Favero A, Micozzi A, Martino P, Bistoni F. Molecular typing of fluoroquinolone-resistant and fluoroquinolone-susceptible escherichia coli isolated from blood of neutropenic cancer patients in a single center. Clin Microbiol Infect [Internet]. 1999;5(8):457-61 (**IF: 5.197**).
20. Menichetti F, **Tascini C**, Ferranti S, Moroni A, Baldoni L, Bozza S, Fedele M, Bifarini G, Del Favero A, Bistoni F. Clinical and molecular epidemiology of an outbreak of infusion-related acinetobacter baumannii bacteremia in an intensive care unit. Infez Med [Internet]. 2000;8(1):24-9.
21. Todisco T, Eslami A, Baglioni S, Sposini T, **Tascini C**, Sommer E, Knoch M. Basis for nebulized antibiotics: Droplet characterization and in vitro antimicrobial activity versus staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. J Aerosol Med Deposition Clear Eff Lung [Internet]. 2000;13(1):11-6.
22. Baldelli F, Preziosi R, Francisci D, **Tascini C**, Bistoni F, Nicoletti I. Programmed granulocyte neutrophil death in patients at different stages of HIV infection. AIDS [Internet]. 2000;14(8):1067-9 (**IF: 2,69**).
23. **Tascini C**, Ferranti S, Messina F, Menichetti F. In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against a multiresistant pseudomonas aeruginosa isolate [3]. Clin Microbiol Infect [Internet]. 2000;6(12):690-1 (**IF: 5.197**).
24. Messina F, Doria R, Gabriellini G, Sartini MS, **Tascini C**, Menichetti F. Bartonella henselae neuroretinitis. Clin Microbiol Infect [Internet]. 2001;7(7):387-8 (**IF: 5.197**).
25. Maggi F, Fornai C, Vatteroni ML, Siciliano G, Menichetti F, **Tascini C**, Specter S, Pistello M, Bendinelli M. Prevalence and genotypic distribution of TT virus in athens, greece. J Med Virol [Internet]. 2001;65(2):423-9 (**IF: 1,998**).
26. **Tascini C**, Ferranti S, Gemignani G, Messina F, Menichetti F. Clinical microbiological case: Fever and headache in a heavy consumer of eucalyptus extract. Clin Microbiol Infect [Internet]. 2002;8(7) (**5.197**)
27. **Tascini C**, Tagliaferri E, Iapoce R, Leonildi A, Menichetti F. Caspofungin in combination with itraconazole and amphotericin B for the treatment of invasive aspergillosis in humans, with a method to test ex vivo synergism [1]. Clin Microbiol Infect [Internet]. 2003;9(8):901-2 (**IF: 5.197**).
28. **Tascini C**, Gemignani G, Leonildi A, Menichetti F. Ex-vivo synergism: A method for optimizing antimicrobial combinations for difficult-to-treat enterococcal endocarditis. J Chemother [Internet]. 2003;15(6):613-5 (**IF: 1,604**).
29. **Tascini C**, Gemignani G, Ferranti S, Tagliaferri E, Leonildi A, Lucarini A, Menichetti F. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant *Pseudomonas aeruginosa* infections. J Chemother [Internet]. 2004;16(3):282-7 (**IF: 1,604**).
30. **Tascini C**, Doria R, Leonildi A, Martinelli C, Menichetti F. Efficacy of the combination ampicillin plus ceftriaxone in the treatment of a case of enterococcal endocarditis due to *Enterococcus faecalis* highly resistant to gentamicin: Efficacy of the "ex vivo" synergism method. J Chemother [Internet]. 2004;16(4):400-3 (**IF: 1,604**).
31. **Tascini C**, Menichetti F, Stefanelli A, Loni C, Lambelet P. Clinical efficacy of intravenous colistin therapy in combination with ceftazidime in severe MDR P. aeruginosa systemic infections in two haematological patients. Infez Med [Internet]. 2006;14(1):41-4.
32. **Tascini C**, Bongiorni MG, Gemignani G, Soldati E, Leonildi A, Arena G, Doria R, Giannola G, La Pira F, Tagliaferri E, Caravelli P, Dell'Anna R, Menichetti F. Management of cardiac device infections: A retrospective survey of a non-surgical approach combining antibiotic therapy with transvenous removal. J Chemother [Internet]. 2006;18(2):157-63 (**IF: 1,604**).
33. Menichetti F, Bindi ML, **Tascini C**, Urbani L, Biancofiore G, Doria R, Esposito M, Mozzo R, Catalano G, Filipponi F. Fever, mental impairment, acute anemia, and renal failure in patient undergoing orthotopic liver transplantation: Posttransplantation malaria. Liver Transplant [Internet]. 2006;12(4):674-6 (**IF: 2.61**).
34. Ferranti S, Leonildi A, Menichetti F, **Tascini C**. Breakthrough fusarium sp probable pneumonia during fluconazole therapy in an AIDS patient with diabetes, candidemia, *Pneumocystis carinii* pneumonia and cytomegalovirus disseminated infection [2]. J Chemother [Internet]. 2006;18(2):227-8 (**IF: 1,604**).
35. **Tascini C**, Menichetti F, Gemignani G, Palumbo F, Leonildi A, Tedeschi A, Piaggesi A. Clinical and microbiological efficacy of colistin therapy in combination with rifampin and imipenem in multidrug-resistant *Pseudomonas aeruginosa* diabetic foot infection with osteomyelitis. Int J Lower Extremity Wounds [Internet]. 2006;5(3):213-6 (**IF: 1.366**).
36. **Tascini C**, Gemignani G, Palumbo F, Leonildi A, Tedeschi A, Lambelet P, Lucarini A, Piaggesi A, Menichetti F. Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant *Pseudomonas aeruginosa* diabetic foot infections with or without osteomyelitis. J Chemother [Internet]. 2006;18(6):648-51 (**IF: 1,604)**.
37. **Tascini C**, Bongiorni MG, Leonildi A, Giannola G, Soldati E, Arena G, Doria R, Germenia C, Menichetti F. Pacemaker endocarditis with pulmonary cavitary lesion due to *Scedosporium prolificans*. J Chemother [Internet]. 2006;18(6):667-9 (**IF: 1,604**).
38. Biancofiore G, **Tascini C**, Bisà M, Gemignani G, Bindi ML, Leonildi A, Giannotti G, Menichetti F. Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant *Acinetobacter baumannii* multifocal infection. A case report. Minerva Anestesiol [Internet]. 2007;73(3):181-5 (IF: ).
39. Biancofiore G, Bisà M, Bindi LM, Urbani L, **Tascini C**, Menichetti F, Filipponi F. Liver transplantation due to herpes simplex virus-related sepsis causing massive hepatic necrosis after thoracoscopic thymectomy. Minerva Anestesiol [Internet]. 2007;73(5):319-22 (**IF: 2.036**).
40. Gemignani G, **Tascini C**, Leonildi A, Piaggesi A, Menichetti F. Activity of ulifloxacin against clinical hospital isolates. Infez Med [Internet]. 2007;15(3):169-73.
41. **Tascini C**, Urbani L, Biancofiore G, Rossolini GM, Leonildi A, Gemignani G, Bindi ML, Mugnaioli C, Filipponi F, Menichetti F. Colistin in combination with rifampin and imipenem for treating a blaVIM-1 metallo-β-lactamase-producing *Enterobacter cloacae* disseminated infection in a liver transplant patient. Minerva Anestesiol [Internet]. 2008;74(1-2):47-9 (**IF: 2.036**).
42. Lazzeri E, Erba P, Perri M, **Tascini C**, Doria R, Giorgetti J, Mariani G. Scintigraphic imaging of vertebral osteomyelitis with 111in-biotin. Spine [Internet]. 2008;33(7) (**IF: 2.297**)
43. Urbani L, Mazzoni A, Colombatto P, Biancofiore G, Bindi L, **Tascini C**, Menichetti F, Brunetto M, Scatena F, Filipponi F. Potential applications of extracorporeal photopheresis in liver transplantation. Transplant Proc [Internet]. 2008;40(4):1175-8 (**IF: 1.06**).
44. Urbani L, Mazzoni A, Bianco I, Grazzini T, De Simone P, Catalano G, Montin U, Petruccelli S, Morelli L, Campani D, Pollina L, Biancofiore G, Bindi L, **Tascini C**, Menichetti F, Scatena F, Filipponi F. The role of immunomodulation in ABO-incompatible adult liver transplant recipients. J Clin Apheresis [Internet]. 2008;23(2):55-62 (**IF: 2.432**) .
45. Cordani S, Manna A, Vignali M, **Tascini C**. Bronchoalveolar lavage as a diagnostic tool in patients with haematological malignancies and pneumonia. Infez Med [Internet]. 2008;16(4):209-13.
46. Urbani L, Mazzoni A, Colombatto P, Bindi L, Biancofiore G, **Tascini C**, Menichetti F, Brunetto MR, Scatena F, Filipponi F. A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers. Transplantation [Internet]. 2008;86(12):1666-71 (**IF: 3.655**).
47. Urbani L, Mazzoni A, Bindi L, Biancofiore G, Bisà M, Meacci L, Esposito M, Mozzo R, Colombatto P, Bianco I, Grazzini T, Coletti L, De Simone P, Catalano G, Montin U, Tincani G, Balzano E, Petruccelli S, Carrai P, **Tascini C**, Menichetti F, Scatena F, Filipponi F. A single-staggered dose of calcineurin inhibitor may be associated with neurotoxicity and nephrotoxicity immediately after liver transplantation. Clin Transplant [Internet]. 2009;23(6):853-60 (**IF: 1.522**).
48. **Tascini C**, Urbani L, Doria R, Catalano G, Leonildi A, Filipponi F, Menichetti F. Breakthrough *Fusarium* spp fungemia during caspofungin therapy in an abo-incompatible orthotopic liver transplant patient. J Chemother [Internet]. 2009;21(2):237-8 (**IF: 1,604**).
49. **Tascini C**, Gemignani G, Doria R, Biancofiore G, Urbani L, Mosca C, Malacarne P, Papineschi F, Passaglia C, Dal Canto L, Procaccini M, Furneri G, Didoni G, Filipponi F, Menichetti F. Linezolid treatment for gram-positive infections: A retrospective comparison with teicoplanin. J Chemother [Internet]. 2009;21(3):311-6 (**IF: 1,604**).
50. Giannarini G, **Tascini C**, Selli C. Prulifloxacin: Clinical studies of a broad-spectrum quinolone agent. Future Microbiol [Internet]. 2009;4(1):13-24 (**IF: 3.637**).
51. **Tascini C**, Tagliaferri E, Di Paolo A, Ciofi L, Del Tacca M, Lambelet P, Menichetti F. Three-times weekly teicoplanin as outpatient treatment of chronic osteoarticular infections. J Chemother [Internet]. 2009;21(4):421-5 (**IF: 1,604**).
52. Polillo M, **Tascini C**, Lastella M, Malacarne P, Ciofi L, Viaggi B, Bocci G, Menichetti F, Danesi R, Del Tacca M, Di Paolo A. A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma. Ther Drug Monit [Internet]. 2010;32(2):200-5 (**IF: 2.376**).
53. Lazzeri E, Erba P, Perri M, Doria R, **Tascini C**, Mariani G. Clinical impact of SPECT/CT with in-111 biotin on the management of patients with suspected spine infection. Clin Nucl Med [Internet]. 2010;35(1):12-7.
54. **Tascini C**, Tagliaferri E, Menichetti F. On antimicrobial resistance among *P. aeruginosa* and enterobacteriaceae. Minerva Anestesiol [Internet]. 2010;76(6):466 (**IF: 3.931**).
55. Piaggesi A, Goretti C, Mazzurco S, **Tascini C**, Leonildi A, Rizzo L, Tedeschi A, Gemignani G, Menichetti F, Del Prato S. A randomized controlled trial to examine the efficacy and safety of a new super-oxidized solution for the management of wide postsurgical lesions of the diabetic foot. Int J Lower Extremity Wounds [Internet]. 2010;9(1):10-5 (**IF: 1.366**).
56. **Tascini C**, Polidori M, Flammini S, Fondelli S, Mencarini J, Vetrano U, Lambelet P, Tagliaferri E, Menichetti F. Acute varicella-zoster virus necrotizing menmgoencephalomyelitis with sudden visual loss and paraparesis in an HIV-infected patient. New Microbiol [Internet]. 2010;33(3):267-9 (**IF: 1.78**) .
57. Polidori M, Tagliaferri E, **Tascini C**, Andreotti G, Flammini S, Menichetti F. Myelitis due to enterovirus in patient on interferon therapy for chronic hepatitis B: Case report. Clin Immunol [Internet]. 2010;137(1):176-7 (**IF: 3.672** ).
58. Erba PA, Cataldi AG, **Tascini C**, Leonildi A, Manfredi C, Mariani G, Lazzeri E. 111In-DTPA-biotin uptake by *Staphylococcus aureus*. Nucl Med Commun [Internet]. 2010;31(11):994-7 (**IF: 1.453**).
59. Sbrana F, di Paolo A, Pasanisi EM, Tagliaferri E, Arvta C, Puntoni M, Leonildi A, Bigazzi F, Danesi R, Rovai D, **Tascini C**, Menichetti F. Administration interval and daptomycin toxicity: A case report of rhabdomyolysis. J Chemother [Internet]. 2010;22(6):434-5 (**IF: 1,604**).
60. Lazzeri D, Lazzeri S, Figus M, **Tascini C**, Bocci G, Colizzi L, Giannotti G, Lorenzetti F, Gandini D, Danesi R, Menichetti F, Del Tacca M, Nardi M, Pantaloni M. Periorbital necrotising fasciitis. Br J Ophthalmol [Internet]. 2010;94(12):1577-85 (**IF: 3.036**).
61. **Tascini C**, Mantengoli E, Gemignani G, Leonildi A, Di Maggio T, Fondelli S, Rossolini GM, Tagliaferri E, Menichetti F. In vitro synergism of ulifloxacin plus piperacillin/tazobactam against clinical isolates of *Enterobacteriaceae* producing extended-spectrum or AmpC-type β-lactamases. Infez Med [Internet]. 2010;18(4):243-7.
62. Guarracino F, Stefani M, Maremmani P, Corini M, Pini S, **Tascini C**, Menichetti F, Ambrosino N. Influenza A triggered status asthmaticus requiring emergency ECMO. Monaldi Arch Chest Dis Pulm Ser [Internet]. 2010;73(4):162-5.
63. **Tascini C**, Tagliaferri E, Rossolini GM, Mantengoli E, Mirarchi G, Leonildi A, Polidori M, Menichetti F. Cellulitis caused by a methicillin-sensitive staphylococcus aureus isolate harboring panton-valentine toxin in an american soldier returning from iraq. Int J Dermatol [Internet]. 2011;50(2):206-7 (**IF: 1.415**).
64. **Tascini C**, Bongiorni MG, Doria R, Polidori M, Iapoce R, Fondelli S, Tagliaferri E, Soldati E, di Paolo A, Leonildi A, Menichetti F. Linezolid for endocarditis: A case series of 14 patients. J Antimicrob Chemother [Internet]. 2011;66(3):679-82 (IF: 5.093).
65. **Tascini C**, Di Paolo A, Polillo M, Ferrari M, Lambelet P, Danesi R, Menichetti F. Case report of a successful treatment of methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia and MRSA/vancomycin-resistant *Enterococcus faecium* cholecystitis by daptomycin. Antimicrob Agents Chemother [Internet]. 2011;55(5):2458-9 (**IF: 4.476**).
66. **Tascini C**, Piaggesi A, Doria R, Fondelli S, Tagliaferri E, Giani T, Rossolini GM, Menichetti F. Diabetic foot osteomyelitis due to *Klebsiella pneumoniae* carbapenemase-producing *Klebsiella pneumoniae*. Infect Dis Clin Pract [Internet]. 2011;19(4):303-4 (IF: 0,29).
67. Polidori M, Nuccorini A, **Tascini C**, Gemignani G, Iapoce R, Leonild A, Tagliaferri E, Menichetti F. Vancomycin-resistant *Enterococcus faecium* (VRE) bacteremia in infective endocarditis successfully treated with combination daptomycin and tigecycline. J Chemother [Internet]. 2011;23(4):240-1 (**IF: 1,604**).
68. **Tascini C**, Tagliaferri E, Leonildi A, di Lonardo A, Lambelet P, di Paolo A, Menichetti F. Daptomycin blood concentrations and clinical failure: Case report. J Chemother [Internet]. 2011;23(4):238-9 (**IF: 1,604**).
69. **Tascini C**, Piaggesi A, Tagliaferri E, Iacopi E, Fondelli S, Tedeschi A, Rizzo L, Leonildi A, Menichetti F. Microbiology at first visit of moderate-to-severe diabetic foot infection with antimicrobial activity and a survey of quinolone monotherapy. Diabetes Res Clin Pract [Internet]. 2011;94(1):133-9 (**IF: 3.42**).
70. **Tascini C**, Malacarne P, Langer M, Menichetti F, Rossolini GM. The 2011 revolution in antimicrobial susceptibility testing and reporting: What the ICU physicians need to know. Minerva Anestesiol [Internet]. 2012;78(1):88-93 (**IF: 1.78**).
71. Utili R, Cogo A, Cristini F, Prisco V, Sagnelli E, **Tascini C**, Iacoboni C, Capone A, Gattuso G, Angarano G, Petrelli E, Grossi P, Bartezaghi M, Zagni E. Clinical experience with daptomycin in italy: Results from a registry study of the treatment of gram-positive infections between 2006 and 2009. J Chemother [Internet]. 2012;24(2):113-21 (IF: 1,604).
72. Giani T, **Tascini C**, Arena F, Ciullo I, Conte V, Leonildi A, Menichetti F, Rossolini GM. Rapid detection of intestinal carriage of klebsiella pneumoniae producing KPC carbapenemase during an outbreak. J Hosp Infect [Internet]. 2012;81(2):119-22 (IF: 2.655).
73. **Tascini C**, Leonildi A, Ciullo I, Flammini S, Tagliaferri E, Menichetti F. Susceptibility of streptococcus pneumoniae clinical isolates to quinolones. J Chemother [Internet]. 2012;24(3):185-6 (IF: 1,604).
74. Erba PA, Conti U, Lazzeri E, Sollini M, Doria R, De Tommasi SM, Bandera F, **Tascini C**, Menichetti F, Dierckx RAJO, Signore A, Mariani G. Added value of 99mTc-HMPAO-labeled leukocyte SPECT/ CT in the characterization and management of patients with infectious endocarditis. J Nucl Med [Internet]. 2012;53(8):1235-43 (IF: 0.89).
75. **Tascini C**, Flammini S, Leonildi A, Ciullo I, Tagliaferri E, Menichetti F. Comparison of teicoplanin and vancomycin in vitro activity on clinical isolates of staphylococcus aureus. J Chemother [Internet]. 2012;24(4):187-90 (IF: 1,604).
76. Bongiorni MG, **Tascini C**, Tagliaferri E, Cori AD, Soldati E, Leonildi A, Zucchelli G, Ciullo I, Menichetti F. Microbiology of cardiac implantable electronic device infections. Europace [Internet]. 2012;14(9):1334-9. (IF: 4.021)
77. Erba PA, Bandera F, Sollini M, **Tascini C**. The use of 18F-FDG-PET/CT in the diagnostic workup of CIED infections: Another perspective. J Am Coll Cardiol [Internet]. 2012;60(15):1435-6 (IF: 16.503).
78. **Tascini C**, Bongiorni MG, Di Cori A, Di Paolo A, Polidori M, Tagliaferri E, Fondelli S, Soldati E, Ciullo I, Leonildi A, Danesi R, Coluccia G, Menichetti F. Cardiovascular implantable electronic device endocarditis treated with daptomycin with or without transvenous removal. Heart Lung J Acute Crit Care [Internet]. 2012;41(6) (IF: 1.290) .
79. Angheben A, Giaconi E, Menconi M, Casazza G, Najajreh M, Anselmi M, Gobbi F, Bisoffi Z, **Tascini C**, Favre C. Reactivation of chagas disease after a bone marrow transplant in italy: First case report. Blood Transfusion [Internet]. 2012;10(4):542-4 (IF: 1.514).
80. **Tascini C**, Di Paolo A, Poletti R, Flammini S, Emdin M, Ciullo I, Tagliaferri E, Moter A, Menichetti F. Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis. Antimicrob Agents Chemother [Internet]. 2013;57(1):601-2 (IF:4,476).
81. **Tascini C**, Bongiorni MG, Tagliaferri E, Di Paolo A, Flammini S, Soldati E, Leonildi A, Di Cori A, Menichetti F. Micafungin for candida albicans pacemaker-associated endocarditis: A case report and review of the literature. Mycopathologia [Internet]. 2013;175(1-2):129-34 (IF: 1.671).
82. Sbrana F, Malacarne P, Viaggi B, Costanzo S, Leonetti P, Leonildi A, Casini B, **Tascini** **C**, Menichetti F. Carbapenem-sparing antibiotic regimens for infections caused by klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis [Internet]. 2013;56(5):697-700 (IF: 8.886).
83. Campanile F, Mongelli G, Bongiorno D, Adembri C, Ballardini M, Falcone M, Menichetti F, Repetto A, Sabia C, Sartor A, Scarparo C, **Tascini C**, Venditti M, Zoppi F, Stefania S. Worrisome trend of new multiple mechanisms of linezolid resistance in staphylococcal clones diffused in italy. J Clin Microbiol [Internet]. 2013;51(4):1256-9 (IF: 4.068).
84. Di Paolo A, Gori G, **Tascini C**, Danesi R, Del Tacca M. Clinical pharmacokinetics of antibacterials in cerebrospinal fluid. Clin Pharmacokinet [Internet]. 2013;52(7):511-42 (IF: 4.829).
85. **Tascini C**, Tagliaferri E, Giani T, Leonildi A, Flammini S, Casini B, Lewis R, Ferranti S, Rossolini GM, Menichetti F. Synergistic activity of colistin plus rifampin against colistin-resistant kpc-producing klebsiella pneumoniae. Antimicrob Agents Chemother [Internet]. 2013;57(8):3990-3 (IF: 4.476).
86. Di Paolo A, **Tascini C**, Polillo M, Gemignani G, Nielsen EI, Bocci G, Karlsson MO, Menichetti F, Danesi R. Population pharmacokinetics of daptomycin in patients affected by severe gram-positive infections. Int J Antimicrob Agents [Internet]. 2013;42(3):250-5 (IF: 4.097).
87. Erba PA, Sollini M, Conti U, Bandera F, **Tascini C**, De Tommasi SM, Zucchelli G, Doria R, Menichetti F, Bongiorni MG, Lazzeri E, Mariani G. Radiolabeled WBC scintigraphy in the diagnostic workup of patients with suspected device-related infections. JACC Cardiovasc Imaging [Internet]. 2013;6(10):1075-86 (IF: 17.759).
88. Bassetti M, Marchetti M, Chakrabarti A, Colizza S, Garnacho-Montero J, Kett DH, Munoz P, Cristini F, Andoniadou A, Viale P, Rocca GD, Roilides E, Sganga G, Walsh TJ, **Tascini C**, Tumbarello M, Menichetti F, Righi E, Eckmann C, Viscoli C, Shorr AF, Leroy O, Petrikos G, De Rosa FG. A research agenda on the management of intra-abdominal candidiasis: Results from a consensus of multinational experts. Intensive Care Med [Internet]. 2013;39(12):2092-106 (IF: 10.125).
89. Scudeller L, Viscoli C, Menichetti F, Del Bono V, Cristini F, **Tascini C**, Bassetti M, Viale P, Adembri C, Antonelli M, Borgonovo G, Bruno F, Concia E, De Rosa FG, Emmi V, Esposito S, Fumagalli R, Girardis M, Grossi PA, Luzzati R, Malacarne P, Pasero D, Pelosi P, Petrosillo N, Sartelli M, Sganga G, Signorini L, Tetamo R, Tumbarello M, Venditti M. Erratum to: An italian consensus for invasive candidiasis management (ITALIC) (infection DOI: 10.1007/s15010-013-0558-0). Infection [Internet]. 2014;42(1):237 (IF: 2.294).
90. **Tascini C**, Sbrana F, Flammini S, Tagliaferri E, Arena F, Leonildi A, Ciullo I, Amadori F, Di Paolo A, Ripoli A, Lewis R, Rossolini GM, Menichetti F, Lambelet P, Forfori F, Viaggi B, Papini F, Urbani L, Malacarne P. Oral gentamicin gut decontamination for prevention of KPC-producing klebsiella pneumoniae infections: Relevance of concomitant systemic antibiotic therapy. Antimicrob Agents Chemother [Internet]. 2014;58(4):1972-6 (IF: 4-476).
91. Bassetti M, Villa G, Ansaldi F, De Florentiis D, **Tascini C**, Cojutti P, Righi E, Sartor A, Crapis M, De Rosa FG, Pea F, Menichetti F. Risk factors associated with the onset of daptomycin non-susceptibility in staphylococcus aureus infections in critically ill patients. Intensive Care Med [Internet]. 2014;41(2):366-8 (IF: 10.125).
92. Erba PA, Leo G, Sollini M, **Tascini C**, Boni R, Berchiolli RN, Menichetti F, Ferrari M, Lazzeri E, Mariani G. Radiolabelled leucocyte scintigraphy versus conventional radiological imaging for the management of late, low-grade vascular prosthesis infections. Eur J Nucl Med Mol Imaging [Internet]. 2014;41(2):357-68 (IF: 4.46).
93. Scudeller L, Viscoli C, Menichetti F, Del Bono V, Cristini F, Tascini C, Bassetti M, Viale P. An italian consensus for invasive candidiasis management (ITALIC). Infection [Internet]. 2014;42(2):263-79(IF: 2.294).
94. **Tascini C**, Sbrana F, Cardinali G, Ripoli A, Leonildi A, Amadori F, Menichetti F. Arterial blood culture to hasten the diagnosis of candidemia in critically ill patients. Intensive Care Med [Internet]. 2014;40(7):1059-60 (IF: 10.125).
95. Sbrana F, Tagliaferri E, Formichi B, Pasanisi EM, **Tascini C**. Epidemiology and outcome of klebsiella pneumoniae carbapenemase-producing klebsiella pneumoniae in a tertiary level cardiac intensive care unit. Minerva Anestesiol [Internet]. 2014;80(4):510-1.
96. Viaggi B, Sbrana F, **Tascini C.** A dangerous job. Minerva Anestesiol [Internet]. 2014;80(3):393-4 (IF: 1.78).
97. Angheben A, Giaconi E, Menconi M, Casazza G, Najajreh M, Anselmi M, Gobbi F, Bisoffi Z, **Tascini C**, Favre C. Post-transplant reactivation of chagas disease in italy. Blood Transfusion [Internet]. 2014;12(SUPPL.1) (IF: 1.514)
98. Di Paolo A, Polillo M, **Tascini C**, Lewis R, Menichetti F, Danesi R. Different recommendations for daptomycin dosing over time in patients with severe infections. Clin Infect Dis [Internet]. 2014;58(12):1788-9 (IF: 8.886).
99. Viaggi B, **Tascini C**, Menichetti F. The definition of starting point for evaluation of timely adequate antifungal therapy. Intensive Care Med [Internet]. 2014;40(12):1973 (IF: 10.125).
100. Viscoli C, Bassetti M, Castagnola E, Cesaro S, Menichetti F, Ratto S, **Tascini C**, Giacobbe DR. Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: Findings from a multicenter prospective observational study. BMC Infect Dis [Internet]. 2014;14(1) (IF: 2.90)
101. Girmenia C, Viscoli C, Piciocchi A, Cudillo L, Botti S, Errico A, Sarmati L, Ciceri F, Locatelli F, Giannella M, Bassetti M, **Tascini C**, Lombardini L, Majolino I, Farina C, Luzzaro F, Rossolini GM, Rambaldi A. Management of carbapenem resistant klebsiella pneumoniae infections in stem cell transplant recipients: An italian multidisciplinary consensus statement. Haematologica [Internet]. 2015;100(9):e373-6 (IF: 6.671).
102. Urbani L, Masi G, Puccini M, Colombatto P, Vivaldi C, Balestri R, Marioni A, Prosperi V, Forfori F, Licitra G, Leoni C, Paolicchi A, Boraschi P, Lunardi A, **Tascini C**, Castagna M, Buccianti P. Minor-but-complex liver resection: An alternative to major resections for colorectal liver metastases involving the hepato-caval confluence. Medicine [Internet]. 2015;94(29) (IF: 4.256)
103. Fazio C, Neri A, Renna G, Vacca P, Antonetti R, Barbui AM, Daprai L, Lanzafame P, Rossi L, Santino I, **Tascini C**, Vocale C, Stefanelli P. Persistent occurrence of serogroup Y/sequence type (ST)-23 complex invasive meningococcal disease among patients aged five to 14 years, italy, 2007 to 2013. Eurosurveillance [Internet]. 2015;20(45) (IF: 5.98)
104. Russo A, Campanile F, Falcone M, **Tascini C**, Bassetti M, Goldoni P, Trancassini M, Della Siega P, Menichetti F, Stefani S, Venditti M. Linezolid-resistant staphylococcal bacteraemia: A multicentre case-case-control study in italy. Int J Antimicrob Agents [Internet]. 2015;45(3):255-61 (IF: 4.097).
105. **Tascini C**, Lipsky BA, Iacopi E, Ripoli A, Sbrana F, Coppelli A, Goretti C, Piaggesi A, Menichetti F. KPC-producing klebsiella pneumoniae rectal colonization is a risk factor for mortality in patients with diabetic foot infections. Clin Microbiol Infect [Internet]. 2015;21(8):e790.e1,790.e3 (5.197).
106. **Tascini C**, Viaggi B, Menichetti F. Comment on: Infections caused by kpc-producing klebsiella pneumoniae: Differences in therapy and mortality in a multicentre study. J Antimicrob Chemother [Internet]. 2015;70(10):2921 (IF: 5.093).
107. Viaggi B, Sbrana F, Malacarne P, **Tascini C**. Ventilator-associated pneumonia caused by colistin-resistant KPC-producing klebsiella pneumoniae: A case report and literature review. Respir Invest [Internet]. 2015;53(3):124-8 (IF: 0.939).
108. Viaggi B, **Tascini C**, Menichetti F. Acid-suppressant therapy does not influence absorption of azoles used in candidemia. Intensive Care Med [Internet]. 2015;41(3):567 (IF: 10.125).
109. Corte L, Tiecco M, Roscini L, De Vincenzi S, Colabella C, Germani R, **Tascini C**, Cardinali G. FTIR metabolomic fingerprint reveals different modes of action exerted by structural variants of N-alkyltropinium bromide surfactants on escherichia coli and listeria innocua cells. PLoS ONE [Internet]. 2015;10(1) (IF: 4.41)
110. Tagliaferri E, **Tascini C**, Leonildi A, Ciullo I, Amadori F, Menichetti F. Easy synergism for colistin-resistant KPC-producing klebsiella pneumoniae: The E-test with supplemented agar. Clin Microbiol Infect [Internet]. 2015;21(2):e7-8 (IF: 5.197).
111. **Tascini C**, Sozio E, Tintori G, Ripoli A, Sbrana F, Rosselli Del Turco E, Bertolino G, Fortunato S, Carmassi F, Cardinali G, Menichetti F. Peripherally inserted central catheter as a predominant risk factor for candidemia in critically ill patients in internal medicine wards in italy. Intensive Care Med [Internet]. 2015;41(8):1498-9 (IF: 10.125).
112. Stefanelli P, Fazio C, Neri A, Boros S, Renna G, Pompa MG, D'Ancona FP, Caporali MG, Aschbacher R, Barbui AM, Chironna M, Daprai L, Taranto AD, Garlaschi ML, Landini MP, Lanzafame P, Mencacci A, Rossi L, Santino I, Spitaler C, **Tascini C**, Vocale C. Changing epidemiology of infant meningococcal disease after the introduction of meningococcal serogroup C vaccine in italy, 2006-2014. Vaccine [Internet]. 2015;33(31):3678-81 (IF: 3.413).
113. **Tascini C**, Lipsky BA, Iacopi E, Ripoli A, Sbrana F, Coppelli A, Goretti C, Piaggesi A, Menichetti F. KPC-producing klebsiella pneumoniae rectal colonization is a risk factor for mortality in patients with diabetic foot infections. Clin Microbiol Infect [Internet]. 2015;21(8) (IF: 5.197)
114. **Tascini C**, Menichetti F, Merelli M, Farese A, Sozio E, Scarparo C, Viaggi B, Rossolini GM, Bassetti M. Variable incidence of candidemia in patients admitted to ICUs or medical wards of large tertiary-care italian hospitals. Clin Microbiol Infect [Internet]. 2015;21(9):e71-2 (IF: 5.197).
115. Bassetti M, Righi E, Ansaldi F, Merelli M, Scarparo C, Antonelli M, Garnacho-Montero J, Diaz-Martin A, Palacios-Garcia I, Luzzati R, Rosin C, Lagunes L, Rello J, Almirante B, Scotton PG, Baldin G, Dimopoulos G, Nucci M, Munoz P, Vena A, Bouza E, de Egea V, Colombo AL, **Tascini C**, Menichetti F, Tagliaferri E, Brugnaro P, Sanguinetti M, Mesini A, Sganga G, Viscoli C, Tumbarello M. A multicenter multinational study of abdominal candidiasis: Epidemiology, outcomes and predictors of mortality. Intensive Care Med [Internet]. 2015;41(9):1601-10 (IF: 10.125).
116. Meini S, Laureano R, Fani L, **Tascini C**, Galano A, Antonelli A, Rossolini GM. Breakthrough lactobacillus rhamnosus GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis: Case report and review of the literature. Infection [Internet]. 2015; 43(6):777-81 (IF: 2.294).
117. **Tascini C**, Urbani L, Sbrana F, Forfori F, Licitra G, Leoni C, Balestri R, Rossi E, Fortunato S, Leonildi A, Puccini M, Di Paolo A, Ripoli A, Colombatto P, Menichetti F, Buccianti P. Oral administration of gentamicin for prophylaxis of KPC-producing klebsiella pneumoniae gut colonization in patients treated with a novel parenchymal-sparing liver surgery: The GEN-gut study. Intensive Care Med [Internet]. 2016;42(1):124-5 (IF: 10.125).
118. Sbrana F, Malcarne P, Bernardeschi G, Ripoli A, **Tascini C**. Appropriateness of empirical therapy in carbapenem-resistant klebsiella pneumoniae intensive care unit acquired infection: Role of surveillance cultures. Infect Dis [Internet]. 2016;48(8):643-5.
119. **Tascini C**, Sozio E, Viaggi B, Meini S. Reading and understanding an antibiogram. Ital J Med [Internet]. 2016;10(4):289-300 (IF: 0.11).
120. **Tascini C**, Cardinali G, Barletta V, Di Paolo A, Leonildi A, Zucchelli G, Corte L, Colabella C, Roscini L, Consorte A, Pasticci MB, Menichetti F, Bongiorni MG. First case of trichoderma longibrachiatum CIED (cardiac implantable electronic device)-associated endocarditis in a non-immunocompromised host: Biofilm removal and diagnostic problems in the light of the current literature. Mycopathologia [Internet]. 2016; 181(3-4):297-303 (IF: 1.67).
121. Corte L, Roscini L, Colabella C, **Tascini C**, Leonildi A, Sozio E, Menichetti F, Merelli M, Scarparo C, Meyer W, Cardinali G, Bassetti M. Exploring ecological modelling to investigate factors governing the colonization success in nosocomial environment of candida albicans and other pathogenic yeasts. Sci Rep [Internet]. 2016; 6 (IF: 5.578)
122. Sbrana F, Malacarne P, Bassetti M, **Tascini C**, Vegnuti L, Della Siega P, Ripoli A, Ansaldi F, Menichetti F. Risk factors for ventilator associated pneumonia due to carbapenemase-producing klebsiella pneumoniae in mechanically ventilated patients with tracheal and rectal colonization. Minerva Anestesiol [Internet]. 2016;82(6):635-40 (IF: 1.78).
123. Sganga G, **Tascini C**, Sozio E, Carlini M, Chirletti P, Cortese F, Gattuso R, Granone P, Pempinello C, Sartelli M, Colizza S. Focus on the prophylaxis, epidemiology and therapy of methicillin-resistant staphylococcus aureus surgical site infections and a position paper on associated risk factors: The perspective of an italian group of surgeons. World J Emerg Surg [Internet]. 2016;11(1) (IF: 1.583)
124. Lagunes L, Borgatta B, Martín-Gomez MT, Rey-Pérez A, Antonelli M, Righi E, Merelli M, Brugnaro P, Dimopoulos G, Garnacho-Montero J, Colombo AL, Luzzati R, Menichetti F, Muñoz P, Nucci M, Scotton G, Viscoli C, Tumbarello M, Bassetti M, Rello J, Ansaldi F, Scarparo C, Diaz-Martin A, Palacios-Garcia I, Rosin C, Almirante B, Baldin G, Vena A, Bouza E, de Egea V, **Tascini C**, Menichetti F, Tagliaferri E, Sanguinetti M, Mesini A, Sganga G, Busetti M, Pumarola T, Martin MT, Nouér SA, Pelaez T, Raise E, Grandesso S, Del Bono V, Esteves P, Trucchi C, Sartor A, De Pascale G, Posteraro B, Scarparo C, Esteves P. Predictors of choice of initial antifungal treatment in intraabdominal candidiasis. Clin Microbiol Infect [Internet]. 2016;22(8):719-24 (IF: 5.197).
125. Di Pilato V, Arena F, **Tascini C**, Cannatelli A, Henrici De Angelis L, Fortunato S, Giani T, Menichetti F, Rossolini GM. Mcr-1.2, a new mcr variant carried on a transferable plasmid from a colistin-resistant KPC carbapenemase-producing klebsiella pneumoniae strain of sequence type 512. Antimicrob Agents Chemother [Internet]. 2016;60(9):5612-5 (IF: 4.476).
126. Scudeller L, Bassetti M, Concia E, Corrao S, Cristini F, De Rosa FG, Del Bono V, Durante-Mangoni E, Falcone M, Menichetti F, **Tascini C**, Tumbarello M, Venditti M, Viale P, Viscoli C, Mazzone A. MEDical wards invasive candidiasis ALgorithms (MEDICAL):Consensus proposal for management. Eur J Intern Med [Internet]. 2016;34:45-53 (IF: 0.19).
127. **Tascini C**, Falcone M, Bassetti M, De Rosa FG, Sozio E, Russo A, Sbrana F, Ripoli A, Merelli M, Scarparo C, Carmassi F, Venditti M, Menichetti F. Candidemia in patients with body temperature below 37°C and admitted to internal medicine wards: Assessment of risk factors. Am J Med [Internet]. 2016;129(12):1330.e1,1330.e6 (IF: 5.003).
128. **Tascini C**, Sozio E, Salini N, Sbrana F, Ripoli A, Viaggi B, Malacarne P. Risk factors for candidaemia in critically ill patients in intensive care units as compared to internal medicine wards. Infect Dis [Internet]. 2017;49(2):153-4.
129. **Tascini C**, Sozio E, Di Paolo A, Tintori G, Leonildi A, Bertolino G, Carmassi F, Tagliaferri E, Menichetti F, Barchiesi F. Fungicidal activity and PK/PD of caspofungin as tools to guide antifungal therapy in a fluconazole-resistant C. parapsilosis candidemia. Journal of Chemotherapy. 2017; ongoing publication: DOI: 10.1080/1120009X.2017.1289308 (IF 1.604).
130. Carannante N, Rossi M, Fraganza F, Coppola G, Chiesa D, Attanasio V, Sbrana F, Corcione A, **Tascini C**. A high PCT level correlates with disease severity in *Plasmodium falciparum* malaria in children. New Microbiol. 2017 Jan;40(1):72-74 (IF: 1,629).
131. Bassetti M, Peghin M, Carnelutti A, Righi E, Merelli M, Ansaldi F, Trucchi C, Alicino C, Sartor A, Toniutto P, Wauters J, Laleman W, **Tascini C**, Menichetti F, Luzzati R, Brugnaro P, Mesini A, Raviolo S, De Rosa FG, Lagunes L, Rello J, Dimopoulos G, Colombo AL, Nucci M, Vena A, Bouza E, Muñoz P, Tumbarello M, Losito R, Martin-Loeches I, Viscoli C. Clinical characteristics and predictors of mortality in chirrotic patients with candidemia and intra-abdominal candidiasis: a multicenter study.Intensive Care Med. 2017 Mar 7. doi: 10.1007/s00134-017-4717-0. [Epub ahead of print] (IF 10.125).
132. Lambelet P, **Tascini C**, Fortunato S, Stefanelli A, Simonetti F, Vettori C, Leonildi A, Menichetti F. Oral gentamicin therapy for **KPC-producing *Klebsiella pneumoniae*** gut colonization in haematoloigc patients: a single center experience. New Microbiol. 2017;40:161-164(IF: 1.629).
133. **Tascini C**, Sozio E, Sbrana F, Bertolino G, Ripoli A. Accuracy of point-of-care ultrasound to identify the source of infection in septic patients: a prospective study-comment. Intern Emerg Med. 2017 Dec;12(8):1335-1336. doi: 10.1007/s11739-017-1729-2. Epub 2017 Aug 4.
134. **Tascini C**, Sozio E, Corte L, Sbrana F, Scarparo C, Ripoli A, Bertolino G, Merelli M, Tagliaferri E, Corcione A, Bassetti M, Cardinali G, Menichetti F. The role of biofilm forming on mortality in patients with candidemia: a study derived from real world data. Infect Dis (Lond). 2017 Oct 9:1-6. doi: 10.1080/23744235.2017.1384956. [Epub ahead of print].
135. Meini S, Laureano R, **Tascini C**, Arena F, Fani L, Frullini A, Passaleva MT, Roberts AT, Mannini D, Sbrana F, Ripoli A, Rossolini GM. Clinical outcome of elderly patients with bloodstream infections due to ESBL-producing *Enterobacteriaceae* in an italian Internal Medicine Word. Eur J Intern Med. 2017 Oct 28. pii: S0953-6205(17)30422-3. doi: 10.1016/j.ejim.2017.10.014. [Epub ahead of print] (IF: 2.960).
136. **Tascini C**, Fraganza F, Salani F, Sozio E, Rossi M, Sbrana F, Carannante N, Chiesa MD, Ripoli A, Bertolino G, Di Pietro M, Bartoloni A, Menichetti F; GISA/SIMIT Meningitis Study Group. Protential role of IgM-enriched immunoglobulina s adjuvant treatment for invasive meningococcal disease. Intensive Care Med. 2017 Nov 9. doi: 10.1007/s00134-017-4957.
137. Colabella C, Corte L, Roscini L, Shapaval V, Kohler A, Tafintseva V, **Tascini C**, Cardinali G. Merging FT-IR and NGS for simultaneous phenotypic and genotypic identification of pathogenic Candida species.PLoS One. 2017 Dec 4;12(12):e0188104. doi: 10.1371/journal.pone.0188104. eCollection 2017.
138. Di Caprio G, Carannante N, Bernardo M, Cuccurullo S, Pallotto C, **Tascini C**. Increased rate of penicllin non –susceptible strains of N. meningitidis in Naples, Italy. J Chemother. 2017 Dec;29(6):389-390. doi: 10.1080/1120009X.2017.1351730. Epub 2017 Jul 20.
139. Sbrana F, Sozio E, Bassetti M, Ripoli A, Pieralli F, Azzini AM, Morettini A, Nozzoli C, Merelli M, Rizzardo S, Bertolino G, Carrara D, Scarparo C, Concia E, Menichetti F, **Tascini C**. Indipendent risk factors for mortality in critically ill patients with candidemia on internal Medicine Wards. Intern Emerg Med. 2018 Jan 10. doi: 10.1007/s11739-017-1783-9. [Epub ahead of print].
140. Carannante N, Pallotto C, Bernardo M, Di Caprio G, **Tascini C**. Treatment of a KPC-producing *Klebsiella pneumoniae* cellulitis and gut decolonization with ceftazidime avibactam in a migran from Lybia*.* J Chemother. 2018 Jan 16:1-2. doi: 10.1080/1120009X.2018.1424504 (IF: 1.577).
141. Rossi M, **Tascini C**, Carannante N, Di Caprio G, Sofia S, Iacobello C. Neurobrucellosis: diagnostic and clinical management of an atypical case. New Microbiol. 2018 Jan 31;41(1). (IF: 1.629).
142. di Russo P, **Tascini C**, Benini ME, Martini C, Lepori P. C1-C2 arthrodesis after spontaneous *Propionibacterium acnes* spondylodiscitis: Case report and literature analysis. Surg Neurol Int. 2018 Jan 22;9:14. doi: 10.4103/sni.sni\_96\_17. eCollection 2018.
143. Vassiliou AG, Kotanidou A, Mastora Z, **Tascini C**, Cardinali G, Orfanos SE. The H3 Haplotype of the EPCR Gene Determines High sEPCR Levels in Critically Ill Septic Patients. Infect Dis Ther. 2018 Mar;7(Suppl 1):3-14. doi: 10.1007/s40121-018-0193-2. Epub 2018 Mar 16.
144. Roscini L, Vassiliou A, Corte L, Casagrande Pierantoni D, Robert V, **Tascini C**, Mattana S, Alunni Cardinali M, Orfanos SE, Fioretto D, Cardinali G. Yeast Biofilm as a Bridge Between Medical and Environmental Microbiology Across Different Detection Techniques. Infect Dis Ther. 2018 Mar;7(Suppl 1):27-34. doi: 10.1007/s40121-018-0191-4. Epub 2018 Mar 16.
145. Bongiorni MG, Burri H, Deharo JC, Stark C, Kennergren C, Saghy L, Rao A, **Tascini C**, Lever N, Kutarski A, Fernandez Lozano I, Strathmore N, Costa R, Epstein L, Love C, Blomstrom-Lundqvist C; ESC Scientific Document Group . 2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHRS. Europace. 2018; 20: 1217. (IF: 5.231).
146. Menichetti F, Falcone M, Lopalco P, **Tascini C**, Pan A, Busani L, Viaggi B, Rossolini GM, Arena F, Novelli A, De Rosa F, Iannazzo S, Cohen J; for GISA (Italian Group for Antimicrobial Stewardship). The GISA call to action for the appropriate use of antimicrobials and the control of antimicrobial resistance in Italy. Int J Antimicrob Agents. 2018;52:127-134. (IF: 4.253).
147. Perutelli A, **Tascini C**, Domenici L, Garibaldi S, Baroni C, Cecchi E, Salerno MG. Safety and efficacy of tigecycline in complicated and uncomplicated pelvic inflammatory disease. Eur Rev Med Pharmacol Sci. 2018 Jun;22(11):3595-3601. (IF: 2.387).
148. Piccirilli A, Perilli M, Amicosante G, Conte V, **Tascini C**, Rossolini GM, Giani T. TEM-184, a Novel TEM-Derived Extended-Spectrum β-Lactamase with Enhanced Activity against Aztreonam. Antimicrob Agents Chemother. 2018 Aug 27;62(9). (IF: 4.255).
149. Sozio E, Pieralli F, Azzini AM, Tintori G, Demma F, Furneri G, Sbrana F, Bertolino G, Fortunato S, Meini S, Bragantini D, Morettini A, Nozzoli C, Menichetti F, Concia E, **Tascini C**; GISA/FADOI Candida Study Group. A prediction rule for early recognition of patients with candidemia in Internal Medicine: results from an Italian, multicentric, case-control study. Infection. 2018 Oct;46(5):625-633. (IF: 2.773).
150. Colabella C, Corte L, Roscini L, Bassetti M, **Tascini C**, Mellor JC, Meyer W, Robert V, Vu D, Cardinali G. NGS barcode sequencing in taxonomy and diagnostics, an application in "*Candida*" pathogenic yeasts with a metagenomic perspective. IMA Fungus. 2018 Jun;9(1):91-105. (IF: 4.308).
151. **Tascini C**. Antibiotic stewardship: ripartiamo dalla pratica clinica. Urologia. 2018 Jul;85(1\_suppl):S20-S23.
152. Menichetti F, Fortunato S, Ricci A, Salani F, Ripoli A, **Tascini C**, Fusco FM, Mencarini J, Bartoloni A, Di Pietro M. Invasive Meningococcal Disease due to group C *N. meningitidis* ST11 (cc11): The Tuscany cluster 2015-2016. Vaccine. 2018 Sep 25;36(40):5962-5966. (IF: 3.285).
153. GiViTI Steering Committee, Bertolini G, Nattino G, Tascini C, Poole D, Viaggi B, Carrara G, Rossi C, Crespi D, Mondini M, Langer M, Rossolini GM, Malacarne P. Mortality attributable to different *Klebsiella* susceptibility patterns and to the coverage of empirical antibiotic therapy: a cohort study on patients admitted to the ICU with infection. Intensive Care Med. 2018 Oct;44(10):1709-1719. (IF: 15.008).
154. Pallotto C, Fiorio M, De Angelis V, Ripoli A, Franciosini E, Quondam Girolamo L, Volpi F, Iorio P, Francisci D, **Tascini C**, Baldelli F. Daily bathing with 4% chlorhexidine gluconate in intensive care settings: a randomized controlled trial. Clin Microbiol Infect. 2018 Sep 26. pii: S1198-743X(18)30634-7. (IF: 5.394).
155. Bassetti M, Castaldo N, Cattelan A, Mussini C, Righi E, **Tascini C**, Menichetti F, Mastroianni CM, Tumbarello M, Grossi P, Artioli S, Carannante N, Cipriani L, Coletto D, Russo A, Digaetano M, Losito AR, Peghin M, Capone A, Nicolè S, Vena A; CEFTABUSE Study Group. Ceftolozane/tazobactam for the treatment of serious *Pseudomonas aeruginosa* infections: a multicentre nationwide clinical experience. Int J Antimicrob Agents. 2019 Apr;53(4):408-415. doi: 10.1016/j.ijantimicag .2018.11.001. (IF: 4.253).
156. Bassetti M, Carannante N, Pallotto C, Righi E, Di Caprio G, Bernardo M, Sodano G, Mallardo E, Francisci D, Sartor A, Graziano E, **Tascini C**. KPC-producing Klebsiella pneumoniae gut decolonisation following ceftazidime/avibactam-based combination therapy: A retrospective observational study. J Glob Antimicrob Resist. 2018 Nov 20;17:109-111. (IF: 2.002).
157. **Tascini C**, Sbrana F, Sozio E, Dal Pino B, Bertolino G, Ripoli A, Pallotto C, Emdin M, Sampietro T. Statins during daptomycin therapy: to give or not to give? Minerva Anestesiol. 2019 Jan 4. doi: 10.23736/S0375-9393.18.13393-1. (IF: 2.693).
158. Rossi M, Siani P, Grossi A, Carannante N, Di Caprio G, Borrelli B, Sbrana F, Di Martino F, Sarno M,**Tascini C**. Aseptic meningitis as onset of Kawasaki disease. Minerva Pediatr. 2019 Jan 17. doi: 10.23736/S0026-4946.19.05384-2. (IF: 0.947).
159. Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C, Menichetti F, Viscoli C, Campoli C, Venditti M, De Gasperi A, Mularoni A, **Tascini C**, Parruti G, Pallotto C, Sica S, Concia E, Cultrera R, De Pascale G, Capone A, Antinori S, Corcione S, Righi E, Losito AR, Digaetano M, Amadori F, Giacobbe DR, Ceccarelli G, Mazza E, Raffaelli F, Spanu T, Cauda R, Viale P. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by *Klebsiella pneumoniae* Carbapenemase-producing *K. pneumoniae*. Clin Infect Dis. 2019 Jan 18;68(3):355-364. doi: 10.1093/cid/ciy492. (IF: 8.970).
160. **Tascini C**, Carannante N, Sodano G, Tiberio C, Atripaldi L, Di Caprio G, Sozio E, Sbrana F, Ripoli A, Menchini C, Galli L, Di Sarno R, Chiappini E, Sarno M, Siani P. Neonatal pertussis diagnosis: low procalcitonin level and high lymphocyte count are able to discriminate pertussis from bacterial and viral infections. New Microbiol. 2019 Jan;42(1):49-51. Epub 2019 Feb 20. (IF: 1.568).
161. Meini S, **Tascini C**, Cei M, Sozio E, Rossolini GM. AmpC β-lactamase-producing Enterobacterales: what a clinician should know. Infection. 2019 Mar 6. doi: 10.1007/s15010-019-01291-9. (IF: 2.773).
162. Menichetti F, Bertolino G, Sozio E, Carmignani C, Rosselli Del Turco E, Tagliaferri E, Sbrana F, Ripoli A, Barnini S, Desideri I, Dal Canto L, **Tascini C**; GISA (Italian Group for Antimicrobial Stewardship) Candidemia Study Group. Impact of infectious diseases consultation as a part of an antifungal stewardship programme on candidemia outcome in an Italian tertiary-care, University hospital. J Chemother. 2018 Sep;30(5):304-309. doi: 10.1080/1120009X.2018.1507086. (IF: 1.490).
163. Corte L, Casagrande Pierantoni D, **Tascini C**, Roscini L, Cardinali G. Biofilm Specific Activity: A Measure to Quantify Microbial Biofilm. Microorganisms. 2019 Mar 7;7(3). pii: E73. doi: 10.3390/microorganisms7030073.
164. Sbrana F, Bellacchi P, Domenichini C, Tascini C. A neglected outbreak in a long-term care facility: Scabies. Am J Infect Control. 2019 Mar 15. pii: S0196-6553(19)30067-7. doi: 10.1016/j.ajic.2019.01.025. (IF: 1.929).
165. Russo A, Bassetti M, Ceccarelli G, Carannante N, Losito AR, Bartoletti M, Corcione S, Granata G, Santoro A, Giacobbe DR, Peghin M, Vena A, Amadori F, Segala FV, Giannella M, Di Caprio G, Menichetti F, Del Bono V, Mussini C, Petrosillo N, De Rosa FG, Viale P, Tumbarello M, Tascini C, Viscoli C, Venditti M. Bloodstream infections caused by carbapenem-resistant *Acinetobacter baumannii*: Clinical features, therapy and outcome from a multicenter study. J Infection, 2019; 79, 130-138, ISSN: 0163-4453, doi: 10.1016/j.jinf.2019.05.017 (IF: 5.099).
166. Rizzo V, Di Caprio G, Carannante N, Rescigno C, Rossi M, Bernardo M, Cuccurullo S, Tascini C (2019). Bacteremia, without Endocarditis, due to *Streptococcus gallolyticus* Subspecies gallolyticus in an Infant with Tetralogy of Fallot. J Ped Infect Dis 2019; 14, 201-203, ISSN: 1305-7707, doi: 10.1055/s-0037-1608701 (IF: 2.433).
167. Pallotto C, Fiorio M, De Angelis V, Ripoli A, Franciosini E, Girolamo LQ, Volpi F, Iorio P, Francisci D, Tascini C, Baldelli F (2019). Daily bathing with 4% chlorhexidine gluconate in intensive care settings: a randomized controlled trial. Clin Microbiol Infect 2019; 25, 705-710, ISSN: 1198-743X, doi: 10.1016/j.cmi.2018.09.012 (IF: 6.425).
168. Giacobbe DR, De Rosa FG, Del Bono V, Grossi PA, Pea F, Petrosillo N, Rossolini GM, Tascini C, Tumbarello M, Viale P, Bassetti M. Ceftobiprole: drug evaluation and place in therapy. Exp Rev Anti-Inf Ther 2019; 17, 689-698, ISSN: 1478-7210, doi: 10.1080/14787210.2019.1667229 EA SEP 2019 (IF: 3.090).
169. Esposito P, Sbrana F, Di Toro A, Gombos S, Tascini C. Ceftazidine-avibactam salvage therapy in newborn with KPC-producing *Klebsiella pneumoniae* invasive infections. Min Anestesiol 2019; vol. 85, 804-805, ISSN: 0375-9393, doi: 10.23736/S0375-9393.19.13521-3 (IF: 2.840).
170. **Tascini C**, Aimo A, Arzilli C, Sbrana F, Ripoli A, Ghiadoni L, Bertone C, Passino C, Attanasio V, Sozio E, Taddei E, Murri R, Fantoni M, Paciosi F, Francisci D, Pasticci MB, Pallotto C, Di Caprio G, Carozza A, Maffei S, Emdin M. Procalcitonin, white blood cell count and C-reactive protein as predictors of S. aureus infection and mortality in infective endocarditis. Int J Cardiol. 2020 Feb 15;301:190-194.
171. **Tascini C**, Bertolino G, Sozio E, Sbrana F, Ripoli A, Carmignani C. Antifungal Stewardship Programs and Candidemia.Clin Infect Dis. 2020 Mar 17;70(7):1522-1523.
172. Tascini C, Attanasio V, Ripa M, Carozza A, Pallotto C, Bernardo M, Francisci D, Oltolini C, Palmiero G, Scarpellini P. Ceftobiprole for the treatment of infective endocarditis: A case series.J Glob Antimicrob Resist. 2020 Mar;20:56-59.
173. Guerrini G, Franzetti F, Giacomelli R, Meroni L, Riva A, Scirè CA, Scrivo R, Tavio M, Agostinone A, Airò P, Atzeni F, Bartalesi F, Bazzichi L, Berardicurti O, Cassola G, Castagna A, Castelli F, Cattelan A, Citriniti G, Cristini F, De Rosa F, Fracassi E, Galloway J, La Paglia GMC, Moioli MC, Ripamonti D, Saracino A, Tani C, **Tascini C**, Tieghi T, Tinelli M, Zabotti A, Sarzi-Puttini P, Galli M. Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases. Clin Exp Rheumatol. 2020 Mar-Apr;38(2):245-256.
174. Giacobbe DR, De Rosa FG, Del Bono V, Grossi PA, Pea F, Petrosillo N, Rossolini GM, **Tascini C**, Tumbarello M, Viale P, Bassetti M. Ceftobiprole: drug evaluation and place in therapy. Expert Rev Anti Infect Ther. 2019 Sep;17(9):689-698.
175. Cai T, Tamanini I, Tascini C, Köves B, Bonkat G, Gacci M, Novelli A, Horcajada JP, Bjerklund Johansen TE, Zanel G. Fosfomycin Trometamol versus Comparator Antibiotics for the Treatment of Acute Uncomplicated Urinary Tract Infections in Women: A Systematic Review and Meta-Analysis. J Urol. 2020 Mar;203(3):570-578.
176. Blomström-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni MG, Poole J, Boriani G, Costa R, Deharo JC, Epstein LM, Saghy L, Snygg-Martin U, Starck C, Tascini C, Strathmore N; ESC Scientific Document Group. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Europace. 2020 Apr 1;22(4):515-549.
177. Blomström-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni MG, Poole J, Boriani G, Costa R, Deharo JC, Epstein LM, Saghy L, Snygg-Martin U, Starck C, Tascini C, Strathmore N; ESC Scientific Document Group. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).
178. Casagrande Pierantoni D, Roscini L, Corte L, Bernardo M, Bassetti M, Tascini C, Cardinali G. Qualitative and quantitative change of the tolerance to liposomal amphotericin B triggered by biofilm maturation in *C. parapsilosis*. Med Mycol. 2020 Aug 1;58(6):827-834.
179. Casagrande Pierantoni D, Bernardo M, Mallardo E, Carannante N, Attanasio V, Corte L, Roscini L, Di Fiore L, **Tascini C**, Cardinali G. *Candida palmioleophila* isolation in Italy from two cases of systemic infection, after a CHROMagar and Vitek system mis-identification as *C. albicans*. New Microbiol. 2020 Jan;43(1):47-50.
180. Attanasio V, Di Luca M, Carozza A, Severino S, Pallotto C, Capoluongo N, Palmiero G, Bernardo M, Tascini C. Clinical efficacy of amoxicillin/clavulanate plus cefditoren as de-escalation combination therapy for endocarditis due to strongly biofilm-forming *Enterococcus faecalis*. Infect Dis (Lond). 2020 May;52(5):376-379.
181. Blomström-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni MG, Poole J, Boriani G, Costa R, Deharo JC, Epstein LM, Sághy L, Snygg-Martin U, Starck C, Tascini C, Strathmore N. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020 Jun 1;41(21):2012-2032.
182. Cai T, Tamanini I, Mattevi D, Verze P, Palmieri A, Malossini G, Mirone V, Novelli A, **Tascini C,** Johansen TEB. Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: Results of a pilot study. Int J Antimicrob Agents. 2020 Jul;56(1):105935.
183. Aimo A, Baritussio A, Emdin M, **Tascini C**. Amiodarone as a possible therapy for coronavirus infection. Eur J Prev Cardiol. 2020.
184. Valent F, Gallo T, Mazzolini E, Pipan C, Sartor A, Merelli M, Bontempo G, Marzinotto S, Curcio F, **Tascini C**. A cluster of COVID-19 cases in a small Italian town: a successful example of contact tracing and swab collection. Clin Microbiol Infect. 2020 Aug;26(8):1112-1114.
185. Bassetti M, Giacobbe DR, Aliberti S, Barisione E, Centanni S, De Rosa FG, Di Marco F, Gori A, Granata G, Mikulska M, Petrosillo N, Richeldi L, Santus P, **Tascini C,** Vena A, Viale P, Blasi F; Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Clin Microbiol Infect. 2020 Jul;26(7):880-894.
186. Quartuccio L, Valent F, Pasut E, **Tascini C**, De Vita S. Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy. Joint Bone Spine. 2020 May 20:S1297-319.
187. Bassetti M, Vena A, Giacobbe DR, Falcone M, Tiseo G, Giannella M, Pascale R, Meschiari M, Digaetano M, Oliva A, Rovelli C, Carannante N, Losito AR, Carbonara S, Mariani MF, Mastroianni A, Angarano G, Tumbarello M, **Tascini C,** Grossi P, Mastroianni CM, Mussini C, Viale P, Menichetti F, Viscoli C, Russo A; CEFTABUSE Study Group. Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing *Enterobacterales* Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). Open Forum Infect Dis. 2020 Apr 21;7(5):ofaa139.
188. Quartuccio L, Sonaglia A, Pecori D, Peghin M, Fabris M,**Tascini C**, De Vita S. Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6. J Med Virol. 2020 Jun 9:10.1002/jmv.26149.
189. Quartuccio L, Sonaglia A, McGonagle D, Fabris M, Peghin M, Pecori D, De Monte A, Bove T, Curcio F, Bassi F, De Vita S, **Tascini C.** Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care. J Clin Virol. 2020 Aug;129:104444.
190. Meini S, Pagotto A, Longo B, Vendramin I, Pecori D, Tascini C. Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives. J Clin Med. 2020 Jun 30;9(7):2050.
191. Marinari GM, Anselmino M, Tascini C, Bernante P, Foletto M, Gentileschi P, Morino M, Olmi S, Toppino M, Silecchia G. Bariatric and metabolic surgery during COVID-19 outbreak phase 2 in Italy: why, when and how to restart. Surg Obes Relat Dis. 2020 Jun 24:S1550-7289.
192. Ripoli A, Sozio E, Sbrana F, Bertolino G, Pallotto C, Cardinali G, Meini S, Pieralli F, Azzini AM, Concia E, Viaggi B, **Tascini C**. Personalized machine learning approach to predict candidemia in medical wards. Infection. 2020 Aug 1.
193. Meini S, Zanichelli A, Sbrojavacca R, Iuri F, Roberts AT, Suffritti C, **Tascini C**. Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key? Front Immunol. 2020 Aug 11;11:2014.
194. Meini S, Zanichelli A, Sbrojavacca R, Iuri F, Roberts AT, Suffritti C, **Tascini C.** Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key? Front Immunol. 2020 Aug 11;11:2014.
195. Cojutti PG, Londero A, Della Siega P, Givone F, Fabris M, Biasizzo J, **Tascini C**, Pea F. Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6.Clin Pharmacokinet. 2020 Aug 27:1-10.
196. Vendramin I, Peghin M, **Tascini C**, Livi U. Longest incubation period of Mycobacterium chimaera infection after cardiac surgery. Eur J Cardiothorac Surg. 2020 Aug 30:ezaa292. doi: 10.1093/ejcts/ezaa292. Epub ahead of print. PMID: 32864705.
197. Meini S, Giani T, **Tascini C**. Intussusceptive angiogenesis in Covid-19: hypothesis on the significance and focus on the possible role of FGF2. Mol Biol Rep. 2020 Oct;47(10):8301-8304. doi: 10.1007/s11033-020-05831-7. Epub 2020 Sep 12. PMID: 32920756; PMCID: PMC7486971.
198. Cattaruzza MS, Gorini G, Bosetti C, Boffi R, Lugo A, Veronese C, Carreras G, Santucci C, Stival C, Pacifici R, Zagà V, Gallus S, Giulietti F, Sarzani R, Spannella F, Del Donno M, Tartaglione S, Marrazzo G, Pelaia G, D'Agosto V, Berti A, Voller F, Cardellicchio S, Cresci C, Foschino Barbaro MP, De Palma R, Negrini S, Sicbaldi V, Serafini A, Bisconti M, Refolo L, Landoni G, Rovere P, Veronesi G, Faverio P, Garavello W, Pesci A, Giacobbe R, Martucci P, Parrella R, Scarano F, Aiello M, Chetta A, Franco C, Mangia A, Carrozzi L, Maggi F, Monzani F, Pistelli F, Russo P, Sanna A, Barreca FM, Conti V, Rossi E, Ruli M, Ruli S, Eslami Varzaneh S, Principe R, Guerrini S, Sebastiani A, Galluccio G, Pezzuto A, Ricci A, Casali E, Mastroianni C, Pirina P, Polo F, Beatrice F, Romagnoli M, Baraldo M, Cojutti PG, **Tascini C**, Pecori D, Graziano E, Tinghino B. Covid-19 and the role of smoking: the protocol of the multicentric prospective study COSMO-IT (COvid19 and SMOking in ITaly). Acta Biomed. 2020 Aug 27;91(3):e2020062. doi: 10.23750/abm.v91i3.10373. PMID: 32921714; PMCID: PMC7716969.
199. Meini S, Fortini A, Andreini R, Sechi LA, **Tascini C**. The Paradox of the Low Prevalence of Current Smokers Among COVID-19 Patients Hospitalized in Nonintensive Care Wards: Results From an Italian Multicenter Case-Control Study. Nicotine Tob Res. 2021 Aug 4;23(8):1436-1440. doi: 10.1093/ntr/ntaa188. PMID: 32964233; PMCID: PMC7543586.
200. Gigli GL, Vogrig A, Nilo A, Fabris M, Biasotto A, Curcio F, Miotti V, **Tascini C**, Valente M. HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome. Neurol Sci. 2020 Dec;41(12):3391-3394. doi: 10.1007/s10072-020-04787-7. PMID: 33006723; PMCID: PMC7530349.
201. Sperotto A, Candoni A, Petruzzellis G, Mullai R, Patriarca F, **Tascini C**, Fanin R. Screening procedure for SARS-CoV-2 infection combining triage, nasopharyngeal swab and serological test in allogeneic stem cell transplantation recipients undergoing outpatient posttransplant follow-up. J Med Virol. 2021 Mar;93(3):1244-1246. doi: 10.1002/jmv.26586. Epub 2020 Oct 30. PMID: 33030745; PMCID: PMC7675581.
202. Poole D, Viaggi B**, Tascini C**, Sozio E, Finazzi S. Meningococcal and pneumococcal meningitis in the ICU: an epidemiological report from the Italian GiViTI registry. Minerva Anestesiol. 2021 Feb;87(2):248-250. doi: 10.23736/S0375-9393.20.14984-8. Epub 2020 Oct 14. PMID: 33054018.
203. Pallotto C, Sbrana F, Ripoli A, Lupia T, Corcione S, Paciosi F, Francisci D, Pasticci MB, Sozio E, Bertolino G, Carannante N, Rescigno C, Carozza A, Di Caprio G, Taddei E, Murri R, Fantoni M, Emdin M, Aimo A, De Rosa FG, **Tascini C**. Daptomycin-based aminoglycoside-sparing therapy for streptococcal endocarditis: a retrospective multicenter study. J Chemother. 2021 Oct;33(6):435-439. doi: 10.1080/1120009X.2020.1838830. Epub 2020 Oct 25. PMID: 33103614.
204. Vendramin I, Peghin M, **Tascini C**, Bortolotti U, Livi U. Mycobacterium chimaera infection after cardiac surgery: Catastrophic effects of delayed diagnosis. J Card Surg. 2021 Jan;36(1):408. doi: 10.1111/jocs.15172. Epub 2020 Oct 30. PMID: 33124088.
205. **Tascini C**, Sermann G, Pagotto A, Sozio E, De Carlo C, Giacinta A, Sbrana F, Ripoli A, Castaldo N, Merelli M, Cadeo B, Macor C, De Monte A. Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience. Intern Emerg Med. 2021 Apr;16(3):669-675. doi: 10.1007/s11739-020-02542-6. Epub 2020 Nov 1. PMID: 33131033; PMCID: PMC7603641.
206. Rosignoli C, Petruzzellis G, Radici V, Facchin G, Girgenti M, Stella R, Isola M, Battista M, Sperotto A, Geromin A, Cerno M, Arzese A, Deias P, **Tascini C**, Fanin R, Patriarca F. Risk Factors and Outcome of C. difficile Infection after Hematopoietic Stem Cell Transplantation. J Clin Med. 2020 Nov 16;9(11):3673. doi: 10.3390/jcm9113673. PMID: 33207616; PMCID: PMC7696044.
207. Castaldo N, **Tascini C**, Della Siega P, Peghin M, Pecori D. Clinical presentation and immunological features of Post-Malaria Neurologic Syndrome: a case report and review of literature. Malar J. 2020 Nov 23;19(1):419. doi: 10.1186/s12936-020-03476-2. PMID: 33228672; PMCID: PMC7681770.
208. Catena C, Colussi G, Bulfone L, Da Porto A, **Tascini C**, Sechi LA. Echocardiographic Comparison of COVID-19 Patients with or without Prior Biochemical Evidence of Cardiac Injury after Recovery. J Am Soc Echocardiogr. 2021 Feb;34(2):193-195. doi: 10.1016/j.echo.2020.10.009. Epub 2020 Oct 22. PMID: 33243582; PMCID: PMC7580530.
209. WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Røttingen JA, Swaminathan S. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2. PMID: 33264556; PMCID: PMC7727327.
210. Pecori D, Della Siega P, Sozio E, Barbano E, Mazzoran L, Zanichelli A, Sbrana F, Federico I, Bassi F, Fabris M, Vendramin I, Sbrojavacca R, **Tascini C**. Icatibant in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Case Report. J Investig Allergol Clin Immunol. 2021 Oct 25;31(5):451-452. doi: 10.18176/jiaci.0659. Epub 2020 Dec 4. PMID: 33275101.
211. Giacobbe DR, Ciacco E, Girmenia C, Pea F, Rossolini GM, Sotgiu G, **Tascini C,** Tumbarello M, Viale P, Bassetti M; ISGRI-SITA (Italian Study Group on Resistant Infections of the Italian Society of Anti-infective Therapy). Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. Infect Drug Resist. 2020 Dec 29;13:4697-4711. doi: 10.2147/IDR.S205309. PMID: 33402840; PMCID: PMC7778378.
212. Agostinis P, Bontempo G, Della Siega P, Gerussi V, Pagotto A, Barbano E, Mazzoran L, Calci M, Sponza M, Sbrana F, Fapranzi S, Baritussio A, **Tascini C**. Approach to patients with COVID-19 disease: the procedure in Udine. New Microbiol. 2021 Jan;44(1):66-69. Epub 2020 Dec 16. PMID: 33453703.
213. Sechi LA, Colussi G, Bulfone L, Brosolo G, Da Porto A, Peghin M, Patruno V, **Tascini C**, Catena C. Short-term cardiac outcome in survivors of COVID-19: a systematic study after hospital discharge. Clin Res Cardiol. 2021 Jul;110(7):1063-1072. doi: 10.1007/s00392-020-01800-z. Epub 2021 Jan 22. PMID: 33481096; PMCID: PMC7820534.
214. Quartuccio L, Fabris M, Sonaglia A, Peghin M, Domenis R, Cifù A, Curcio F, **Tascini C**. Interleukin 6, soluble interleukin 2 receptor alpha (CD25), monocyte colony-stimulating factor, and hepatocyte growth factor linked with systemic hyperinflammation, innate immunity hyperactivation, and organ damage in COVID-19 pneumonia. Cytokine. 2021 Apr;140:155438. doi: 10.1016/j.cyto.2021.155438. Epub 2021 Jan 15. PMID: 33493861; PMCID: PMC7810025.
215. Agostinis P, Vianello V, Dereani E, Caruso G, Montessoro B, Taurian M, Di Chiara A, Patruno V, Cavallin F, Fadini GP, Aldovini A, Baritussio A, Curcio F, Tascini C, Baritussio A. Response to a massive SARS-CoV-2 infection in a nursing home transformed into a caring center. Aging Clin Exp Res. 2021 Feb;33(2):443-450. doi: 10.1007/s40520-020-01784-w. Epub 2021 Jan 28. PMID: 33506312; PMCID: PMC7840424.
216. Meini S, Viaggi B, **Tascini C**. Mono vs. combo regimens with novel beta-lactam/beta-lactamase inhibitor combinations for the treatment of infections due to carbapenemase-producing Enterobacterales: insights from the literature. Infection. 2021 Jun;49(3):411-421. doi: 10.1007/s15010-021-01577-x. Epub 2021 Feb 3. Erratum in: Infection. 2021 Mar 19;: PMID: 33534065.
217. De Monte A, Sermann G, Sozio E, Sbrana F, **Tascini C**. Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience: reply. Intern Emerg Med. 2021 Apr;16(3):795-796. doi: 10.1007/s11739-021-02630-1. Epub 2021 Feb 3. PMID: 33534080; PMCID: PMC7854869.
218. Zhanel GG, Kosar J, Baxter M, Dhami R, Borgia S, Irfan N, MacDonald KS, Dow G, Lagacé-Wiens P, Dube M, Bergevin M, **Tascini C**, Keynan Y, Walkty A, Karlowsky J. Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registry. J Glob Antimicrob Resist. 2021 Mar;24:335-339. doi: 10.1016/j.jgar.2021.01.014. Epub 2021 Feb 1. PMID: 33540083.
219. Colabella C, Casagrande Pierantoni D, Corte L, Roscini L, Conti A, Bassetti M, **Tascini C**, Robert V, Cardinali G. Single Strain High-Depth NGS Reveals High rDNA (ITS-LSU) Variability in the Four Prevalent Pathogenic Species of the Genus Candida. Microorganisms. 2021 Feb 2;9(2):302. doi: 10.3390/microorganisms9020302. PMID: 33540602; PMCID: PMC7912828.
220. Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, De Rosa FG, Sarmati L, Bassetti M, Brindicci G, Rossi M, Luzzati R, Grossi PA, Corona A, Capone A, Falcone M, Mussini C, Trecarichi EM, Cascio A, Guffanti E, Russo A, De Pascale G, **Tascini C**, Gentile I, Losito AR, Bussini L, Corti G, Ceccarelli G, Corcione S, Compagno M, Giacobbe DR, Saracino A, Fantoni M, Antinori S, Peghin M, Bonfanti P, Oliva A, De Gasperi A, Tiseo G, Rovelli C, Meschiari M, Shbaklo N, Spanu T, Cauda R, Viale P. Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study. Clin Infect Dis. 2021 Nov 2;73(9):1664-1676. doi: 10.1093/cid/ciab176. PMID: 33618353.
221. Sozio E, **Tascini C**, Fabris M, D'Aurizio F, De Carlo C, Graziano E, Bassi F, Sbrana F, Ripoli A, Pagotto A, Giacinta A, Gerussi V, Visentini D, De Stefanis P, Merelli M, Saeed K, Curcio F. MR-proADM as prognostic factor of outcome in COVID-19 patients. Sci Rep. 2021 Mar 4;11(1):5121. doi: 10.1038/s41598-021-84478-1. PMID: 33664308; PMCID: PMC7933259.
222. Gerussi V, Peghin M, Palese A, Bressan V, Visintini E, Bontempo G, Graziano E, De Martino M, Isola M, **Tascini C**. Vaccine Hesitancy among Italian Patients Recovered from COVID-19 Infection towards Influenza and Sars-Cov-2 Vaccination. Vaccines (Basel). 2021 Feb 18;9(2):172. doi: 10.3390/vaccines9020172. PMID: 33670661; PMCID: PMC7922251.
223. Andreoni M, Bassetti M, Corrao S, De Rosa FG, Esposito V, Falcone M, Grossi P, Pea F, Petrosillo N, **Tascini C**, Venditti M, Viale P. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. Expert Rev Anti Infect Ther. 2021 Sep;19(9):1125-1134. doi: 10.1080/14787210.2021.1894130. Epub 2021 Mar 16. PMID: 33682593.
224. De Vivo S, Barberio M, Corrado C, Severino S, Verde R, Fragranza F, Attena E, Rescigno C, Bernardo M, Innocenti S, **Tascini C**, D'Onofrio A. CRT implantation after transvenous lead/device extraction (TLE) in a patient with COVID-19: Endocarditis triggered by syndrome coronavirus 2 (SARS-COV-2) infection? A case report. Pacing Clin Electrophysiol. 2022 Jun;45(6):807-810. doi: 10.1111/pace.14218. Epub 2022 Apr 29. PMID: 33720392; PMCID: PMC8251177.
225. Saeed K, Legramante JM, Angeletti S, Curcio F, Miguens I, Poole S, **Tascini C**, Sozio E, Del Castillo JG. Mid-regional pro-adrenomedullin as a supplementary tool to clinical parameters in cases of suspicion of infection in the emergency department. Expert Rev Mol Diagn. 2021 Apr;21(4):397-404. doi: 10.1080/14737159.2021.1902312. Epub 2021 Mar 29. PMID: 33736553.
226. Meini S, Viaggi B, **Tascini C**. Correction to: Mono vs. combo regimens with novel beta-lactam/beta-lactamase inhibitor combinations for the treatment of infections due to carbapenemase-producing Enterobacterales: insights from the literature. Infection. 2021 Jun;49(3):423-425. doi: 10.1007/s15010-021-01596-8. Erratum for: Infection. 2021 Jun;49(3):411-421. PMID: 33742365.
227. Bax F, **Tascini C**, Valente M, Marini A, Surcinelli A, Pellitteri G, De Carlo C, Gerussi V, Gigli GL. Hyposmia and Dysgeusia in COVID-19: Indication to Swab Test and Clue of CNS Involvement. Neurol Clin Pract. 2021 Apr;11(2):e92-e96. doi: 10.1212/CPJ.0000000000001029. PMID: 33842076; PMCID: PMC8032441.
228. Cojutti PG, Londero A, Della Siega P, Givone F, Fabris M, Biasizzo J, **Tascini C**, Pea F. Authors' Reply to Cattaneo et al.: "Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6". Clin Pharmacokinet. 2021 Jun;60(6):833-834. doi: 10.1007/s40262-021-00996-1. Epub 2021 Apr 17. PMID: 33864624; PMCID: PMC8052551.
229. Casagrande Pierantoni D, Corte L, Casadevall A, Robert V, Cardinali G, **Tascini C**. How does temperature trigger biofilm adhesion and growth in Candida albicans and two non-Candida albicans Candida species? Mycoses. 2021 Nov;64(11):1412-1421. doi: 10.1111/myc.13291. Epub 2021 May 9. PMID: 33894074; PMCID: PMC8597170.
230. Meini S, Sozio E, Bertolino G, Sbrana F, Ripoli A, Pallotto C, Viaggi B, Andreini R, Attanasio V, Rescigno C, Atripaldi L, Leonardi S, Bernardo M, **Tascini C**. D-Dimer as Biomarker for Early Prediction of Clinical Outcomes in Patients With Severe Invasive Infections Due to Streptococcus Pneumoniae and Neisseria Meningitidis. Front Med (Lausanne). 2021 Apr 15;8:627830. doi: 10.3389/fmed.2021.627830. PMID: 33937280; PMCID: PMC8081958.
231. Quartuccio L, Valent F, Pasut E, **Tascini C**, De Vita S. Prévalence du COVID-19 chez les patients atteints de rhumatismes inflammatoires chroniques traités par biothérapies ou inhibiteurs des JAK : une étude basée sur la population au cours des deux premiers mois de l’épidémie de COVID-19 en Italie. Rev Rhum Ed Fr. 2021 Oct;88(5):377-381. French. doi: 10.1016/j.rhum.2021.05.004. Epub 2021 May 14. PMID: 34007141; PMCID: PMC8120792.
232. Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, Bontempo G, Marrella F, Tommasini A, Fabris M, Curcio F, Isola M, **Tascini C.** Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021 Oct;27(10):1507-1513. doi: 10.1016/j.cmi.2021.05.033. Epub 2021 Jun 7. PMID: 34111579; PMCID: PMC8180450.
233. Silecchia G, Boru CE, M Marinari G, Gentileschi P, Morino M, Olmi S, Foletto M, Bernante P, Morganti R, **Tascini C**, Anselmino M, Bianciardi E, Campanelli M, Fiorello L, Mancini R, Oldani A, Rottoli M, Salzano A, Trotta M; cooperative RESTART group. Laparoscopic bariatric surgery is safe during phase 2-3 of COVID-19 pandemic in Italy: A multicenter, prospective, observational study. Diabetes Res Clin Pract. 2021 Jul;177:108919. doi: 10.1016/j.diabres.2021.108919. Epub 2021 Jun 13. PMID: 34133962; PMCID: PMC8200253.
234. Sozio E, De Monte A, Sermann G, Bassi F, Sacchet D, Sbrana F, Ripoli A, Curcio F, Fabris M, Marengo S, Italiani D, Luciana Boccalatte-Rosa D, **Tascini C**; CORMOR study Group. CORonavirus-19 mild to moderate pneumonia Management with blood Ozonization in patients with Respiratory failure (CORMOR) multicentric prospective randomized clinical trial. Int Immunopharmacol. 2021 Sep;98:107874. doi: 10.1016/j.intimp.2021.107874. Epub 2021 Jun 12. PMID: 34186281; PMCID: PMC8196321.
235. Sozio E, Bertini A, Bertolino G, Sbrana F, Ripoli A, Carfagna F, Giacinta A, Viaggi B, Meini S, Ghiadoni L, **Tascini C**. Recognition in Emergency Department of Septic Patients at Higher Risk of Death: Beware of Patients without Fever. Medicina (Kaunas). 2021 Jun 12;57(6):612. doi: 10.3390/medicina57060612. PMID: 34204613; PMCID: PMC8231120.
236. Bassetti M, Giacobbe DR, Bruzzi P, Barisione E, Centanni S, Castaldo N, Corcione S, De Rosa FG, Di Marco F, Gori A, Gramegna A, Granata G, Gratarola A, Maraolo AE, Mikulska M, Lombardi A, Pea F, Petrosillo N, Radovanovic D, Santus P, Signori A, Sozio E, Tagliabue E, **Tascini C**, Vancheri C, Vena A, Viale P, Blasi F; Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infect Dis Ther. 2021 Dec;10(4):1837-1885. doi: 10.1007/s40121-021-00487-7. Epub 2021 Jul 30. PMID: 34328629; PMCID: PMC8323092.
237. Peghin M, Bouza E, Fabris M, De Martino M, Palese A, Bontempo G, Graziano E, Gerussi V, Bressan V, Sartor A, Isola M, **Tascini C**, Curcio F. Low risk of reinfections and relation with serological response after recovery from the first wave of COVID-19. Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2597-2604. doi: 10.1007/s10096-021-04335-x. Epub 2021 Aug 11. PMID: 34378086; PMCID: PMC8354681.
238. Peghin M, De Martino M, Fabris M, Palese A, Visintini E, Graziano E, Gerussi V, Bontempo G, D'Aurizio F, Biasotto A, Sartor A, Pipan C, Marzinotto S, Curcio F, Bouza E, Isola M, **Tascini C**. The Fall in Antibody Response to SARS-CoV-2: a Longitudinal Study of Asymptomatic to Critically Ill Patients Up to 10 Months after Recovery. J Clin Microbiol. 2021 Oct 19;59(11):e0113821. doi: 10.1128/JCM.01138-21. Epub 2021 Aug 11. PMID: 34379530; PMCID: PMC8525561.
239. Coloretti I, Berlot G, Busani S, De Rosa FG, Donati A, Forfori F, Grasselli G, Mirabella L, **Tascini C**, Viale P, Girardis M. Rationale for Polyclonal Intravenous Immunoglobulin Adjunctive Therapy in COVID-19 Patients: Report of a Structured Multidisciplinary Consensus. J Clin Med. 2021 Aug 8;10(16):3500. doi: 10.3390/jcm10163500. PMID: 34441796; PMCID: PMC8396919.
240. Pagano L, Salmanton-García J, Marchesi F, Busca A, Corradini P, Hoenigl M, Klimko N, Koehler P, Pagliuca A, Passamonti F, Verga L, Víšek B, Ilhan O, Nadali G, Weinbergerová B, Córdoba-Mascuñano R, Marchetti M, Collins GP, Farina F, Cattaneo C, Cabirta A, Gomes-Silva M, Itri F, van Doesum J, Ledoux MP, Čerňan M, Jakšić O, Duarte RF, Magliano G, Omrani AS, Fracchiolla NS, Kulasekararaj A, Valković T, Poulsen CB, Machado M, Glenthøj A, Stoma I, Ráčil Z, Piukovics K, Navrátil M, Emarah Z, Sili U, Maertens J, Blennow O, Bergantim R, García-Vidal C, Prezioso L, Guidetti A, Del Principe MI, Popova M, de Jonge N, Ormazabal-Vélez I, Fernández N, Falces-Romero I, Cuccaro A, Meers S, Buquicchio C, Antić D, Al-Khabori M, García-Sanz R, Biernat MM, Tisi MC, Sal E, Rahimli L, Čolović N, Schönlein M, Calbacho M, **Tascini C**, Miranda-Castillo C, Khanna N, Méndez GA, Petzer V, Novák J, Besson C, Duléry R, Lamure S, Nucci M, Zambrotta G, Žák P, Seval GC, Bonuomo V, Mayer J, López-García A, Sacchi MV, Booth S, Ciceri F, Oberti M, Salvini M, Izuzquiza M, Nunes-Rodrigues R, Ammatuna E, Obr A, Herbrecht R, Núñez-Martín-Buitrago L, Mancini V, Shwaylia H, Sciumè M, Essame J, Nygaard M, Batinić J, Gonzaga Y, Regalado-Artamendi I, Karlsson LK, Shapetska M, Hanakova M, El-Ashwah S, Borbényi Z, Çolak GM, Nordlander A, Dragonetti G, Maraglino AME, Rinaldi A, De Ramón-Sánchez C, Cornely OA; EPICOVIDEHA working group. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021 Oct 14;14(1):168. doi: 10.1186/s13045-021-01177-0. PMID: 34649563; PMCID: PMC8515781.
241. Peghin M, Pompei E, Vendramin I, **Tascini C**. Gram-negative bacteria as a cause of mediastinitis after cardiac surgery. Curr Opin Infect Dis. 2021 Dec 1;34(6):710-717. doi: 10.1097/QCO.0000000000000785. PMID: 34654045.
242. Facchin G, Candoni A, Lazzarotto D, Zannier ME, Peghin M, Sozio E, Pellegrini N, Filì C, Sartor A, **Tascini C**, Fanin R. Clinical characteristics and outcome of 125 polymicrobial bloodstream infections in hematological patients: an 11-year epidemiologic survey. Support Care Cancer. 2022 Mar;30(3):2359-2366. doi: 10.1007/s00520-021-06640-9. Epub 2021 Nov 6. PMID: 34741656.
243. Da Porto A, **Tascini C**, Peghin M, Sozio E, Colussi G, Casarsa V, Bulfone L, Graziano E, De Carlo C, Catena C, Sechi LA. Prognostic Role of Malnutrition Diagnosed by Bioelectrical Impedance Vector Analysis in Older Adults Hospitalized with COVID-19 Pneumonia: A Prospective Study. Nutrients. 2021 Nov 15;13(11):4085. doi: 10.3390/nu13114085. PMID: 34836338; PMCID: PMC8621574.
244. Sbrana F, Domenichini C, Bellacchi P, Sozio E, Dal Pino B, **Tascini C**. Doctors and their children: the Pandora's jar of infectious diseases. Minerva Pediatr (Torino). 2021 Dec 3. doi: 10.23736/S2724-5276.21.06224-8. Epub ahead of print. PMID: 34859645.
245. Bassetti M, Giacobbe DR, Bruzzi P, Barisione E, Centanni S, Castaldo N, Corcione S, De Rosa FG, Di Marco F, Gori A, Gramegna A, Granata G, Gratarola A, Maraolo AE, Mikulska M, Lombardi A, Pea F, Petrosillo N, Radovanovic D, Santus P, Signori A, Sozio E, Tagliabue E, **Tascini C**, Vancheri C, Vena A, Viale P, Blasi F; Italian Society of Anti-infective Therapy (SITA), the Italian Society of Pulmonology (SIP). A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infect Dis Ther. 2022 Feb;11(1):635-638. doi: 10.1007/s40121-021-00564-x. Epub 2021 Dec 10. PMID: 34893960; PMCID: PMC8663998.
246. Mio C, Dal Secco C, Marzinotto S, Bruno C, Pimpo S, Betto E, Bertoni M, Pipan C, Sozio E, **Tascini C**, Damante G, Curcio F. Local occurrence and fast spread of B.1.1.7 lineage: A glimpse into Friuli Venezia Giulia. PLoS One. 2021 Dec 14;16(12):e0261229. doi: 10.1371/journal.pone.0261229. PMID: 34905574; PMCID: PMC8670677.
247. Mio C, Dal Secco C, Marzinotto S, Pipan C, Sozio E, **Tascini C**, Damante G, Curcio F. Monitoring the SPREAD of the SARS-CoV-2 lineage B.1.621 in Udine, Italy. J Clin Pathol. 2021 Dec 15;75(10):712–4. doi: 10.1136/jclinpath-2021-207810. Epub ahead of print. PMID: 34911747; PMCID: PMC9510432.
248. Cojutti PG, Carnelutti A, Lazzarotto D, Sozio E, Candoni A, Fanin R, **Tascini C**, Pea F. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles? Pharmaceutics. 2021 Dec 6;13(12):2099. doi: 10.3390/pharmaceutics13122099. PMID: 34959380; PMCID: PMC8708495.
249. Pisapia R, Capoluongo N, Palmiero G, **Tascini C**, Rescigno C. Relapsing Neurological Complications in a Child With ATP1A3 Gene Mutation and Influenza Infection: A Case Report. Front Neurol. 2021 Dec 15;12:774054. doi: 10.3389/fneur.2021.774054. PMID: 34975730; PMCID: PMC8715801.
250. Bulfoni M, Sozio E, Marcon B, De Martino M, Cesselli D, De Carlo C, Martinella R, Migotti A, Vania E, Zanus-Fortes A, De Piero J, Nencioni E, **Tascini C,** Isola M, Curcio F. Validation of a Saliva-Based Test for the Molecular Diagnosis of SARS-CoV-2 Infection. Dis Markers. 2022 Jan 7;2022:6478434. doi: 10.1155/2022/6478434. PMID: 35035611; PMCID: PMC8759915.
251. Corcione S, Lupia T, Pallotto C, Giacobbe DR, De Benedetto I, Stroffolini G, Mornese Pinna S, **Tascini C**, Bassetti M, De Rosa FG, On Behalf Of Sita Giovani Young Investigators Group Of The Società Italiana Terapia Antinfettiva. Beta Lactams Plus Daptomycin Combination Therapy for Infective Endocarditis: An Italian National Survey (BADAS). Antibiotics (Basel). 2022 Jan 2;11(1):56. doi: 10.3390/antibiotics11010056. PMID: 35052933; PMCID: PMC8773184.
252. Candoni A, Petruzzellis G, Sperotto A, Andreotti V, Giavarra M, Corvaja C, Minisini A, Comuzzi C, **Tascini C**, Fanin R, Fasola G. Detection of SARS-CoV-2 infection prevalence in 860 cancer patients with a combined screening procedure including triage, molecular nasopharyngeal swabs and rapid serological test. A report from the first epidemic wave. PLoS One. 2022 Feb 2;17(2):e0262784. doi: 10.1371/journal.pone.0262784. PMID: 35108300; PMCID: PMC8809545.
253. Vetrugno L, Sala A, Orso D, Meroi F, Fabbro S, Boero E, Valent F, Cammarota G, Restaino S, Vizzielli G, Girometti R, Merelli M, **Tascini C**, Bove T, Driul L; PINK-CO study investigators. Lung Ultrasound Signs and Their Correlation With Clinical Symptoms in COVID-19 Pregnant Women: The "PINK-CO" Observational Study. Front Med (Lausanne). 2022 Jan 21;8:768261. doi: 10.3389/fmed.2021.768261. PMID: 35127744; PMCID: PMC8814327.
254. Papst L, Luzzati R, Carević B, **Tascini C**, Gorišek Miksić N, Vlahović Palčevski V, Djordjevic ZM, Simonetti O, Sozio E, Lukić M, Stevanović G, Petek D, Beović B. Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study. Antibiotics (Basel). 2022 Jan 28;11(2):176. doi: 10.3390/antibiotics11020176. PMID: 35203779; PMCID: PMC8868464.
255. Peghin M, De Martino M, Palese A, Gerussi V, Bontempo G, Graziano E, Visintini E, D'Elia D, Dellai F, Marrella F, Fabris M, Curcio F, Sartor A, Isola M, **Tascini C**. Post-COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients. Clin Microbiol Infect. 2022 Aug;28(8):1140-1148. doi: 10.1016/j.cmi.2022.03.016. Epub 2022 Mar 23. PMID: 35339673; PMCID: PMC8940723.
256. Cacopardo B, Cattaneo D, Cortese F, Di Luca M, Falcone M, Marchetti G, **Tascini C**, Tiseo G, Venditti M. Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios. Expert Rev Anti Infect Ther. 2022 Jul;20(7):997-1004. doi: 10.1080/14787210.2022.2060820. Epub 2022 Apr 8. PMID: 35353020.
257. Giuliano S, Angelini J, Flammini S, **Tascini C**. Comment on: Streptococcal and enterococcal endocarditis: time for individualized antibiotherapy? J Antimicrob Chemother. 2022 Jun 29;77(7):2044-2045. doi: 10.1093/jac/dkac109. PMID: 35373298.
258. Fabris M, Del Ben F, Sozio E, Beltrami AP, Cifù A, Bertolino G, Caponnetto F, Cotrufo M, **Tascini C**, Curcio F. Cytokines from Bench to Bedside: A Retrospective Study Identifies a Definite Panel of Biomarkers to Early Assess the Risk of Negative Outcome in COVID-19 Patients. Int J Mol Sci. 2022 Apr 27;23(9):4830. doi: 10.3390/ijms23094830. PMID: 35563218; PMCID: PMC9101406.
259. Palese A, Peghin M, Bressan V, Venturini M, Gerussi V, Bontempo G, Graziano E, Visintini E, **Tascini C**. One Word to Describe My Experience as a COVID-19 Survivor Six Months after Its Onset: Findings of a Qualitative Study. Int J Environ Res Public Health. 2022 Apr 19;19(9):4954. doi: 10.3390/ijerph19094954. PMID: 35564348; PMCID: PMC9106002.
260. Peghin M, Vena A, Graziano E, Giacobbe DR, **Tascini C**, Bassetti M. Improving management and antimicrobial stewardship for bacterial and fungal infections in hospitalized patients with COVID-19. Ther Adv Infect Dis. 2022 May 14;9:20499361221095732. doi: 10.1177/20499361221095732. PMID: 35591884; PMCID: PMC9112312.
261. Peghin M, Castaldo N, **Tascini C**, Bassetti M, Graziano E, Givone F, Savignano C, De Colle MC, Bove T, Pipan C, Loy M, Basso S, Cinque P, Gerevini S, Berastegui C, Hirsch HH, Grossi PA, Comoli P. Successful JC virus-targeted T-cell therapy for progressive multifocal leukoencephalopathy in a lung transplant recipient. J Heart Lung Transplant. 2022 Jul;41(7):991-996. doi: 10.1016/j.healun.2022.04.001. Epub 2022 Apr 12. PMID: 35595631. Bais B, Sozio E, De Silvestri D, Volpetti S, Zannier ME, Filì C, Bassi F, Alcaro L, Cotrufo M, Pagotto A, Giacinta A, Patruno V, Da Porto A, Sbrojavacca R, Curcio F, Tascini C, Sechi LA, Colussi G. Effect of heparin treatment on pulmonary embolism and in-hospital death in unvaccinated COVID-19 patients without overt deep vein thrombosis. Thromb J. 2022 Jun 20;20(1):34. doi: 10.1186/s12959-022-00393-z. PMID: 35725464; PMCID: PMC9207168.
262. Bais B, Sozio E, De Silvestri D, Volpetti S, Zannier ME, Filì C, Bassi F, Alcaro L, Cotrufo M, Pagotto A, Giacinta A, Patruno V, Da Porto A, Sbrojavacca R, Curcio F, **Tascini C**, Sechi LA, Colussi G. Effect of heparin treatment on pulmonary embolism and in-hospital death in unvaccinated COVID-19 patients without overt deep vein thrombosis. Thromb J. 2022 Jun 20;20(1):34. doi: 10.1186/s12959-022-00393-z. PMID: 35725464; PMCID: PMC9207168.
263. Colizzi M, Peghin M, De Martino M, Bontempo G, Gerussi V, Palese A, Isola M, **Tascini C**, Balestrieri M. Mental health symptoms one year after acute COVID-19 infection: Prevalence and risk factors. Rev Psiquiatr Salud Ment. 2022 Jun 17. doi: 10.1016/j.rpsm.2022.05.008. Epub ahead of print. PMID: 35755492; PMCID: PMC9212931.
264. Peghin M, De Martino M, Palese A, Graziano E, Isola M, **Tascini C**. 'Post-COVID-19 syndrome and humoral response association after one year in vaccinated and unvaccinated patients': authors' response. Clin Microbiol Infect. 2022 Oct;28(10):1397-1398. doi: 10.1016/j.cmi.2022.06.003. Epub 2022 Jul 14. PMID: 35842022; PMCID: PMC9279256.
265. Cojutti PG, Tedeschi S, Gatti M, Zamparini E, Meschiari M, Siega PD, Mazzitelli M, Soavi L, Binazzi R, Erne EM, Rizzi M, Cattelan AM, **Tascini C**, Mussini C, Viale P, Pea F. Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring. Antibiotics (Basel). 2022 Jul 24;11(8):996. doi: 10.3390/antibiotics11080996. PMID: 35892386; PMCID: PMC9331863.
266. Corciulo C, Dal Pino B, Visentini D, Bigazzi F, Ripoli A, Sozio E, Curcio F, **Tascini C**, Fabris M, Sampietro T, Sbrana F. Lipid modification induced by lipoprotein apheresis could mirrored mid-regional-pro-adrenomedullin plasma levels? Transfus Apher Sci. 2023 Feb;62(1):103515. doi: 10.1016/j.transci.2022.103515. Epub 2022 Jul 26. PMID: 35927157.
267. Londero A, Fusi M, Cinausero M, **Tascini C,** Gervasoni C, Cattaneo D. Effects of the androgen receptor inhibitor enzalutamide on the pharmacokinetics of dolutegravir and tenofovir: a case report. AIDS. 2022 Sep 1;36(11):1603-1605. doi: 10.1097/QAD.0000000000003269. PMID: 35979833.
268. Beltrami AP, De Martino M, Dalla E, Malfatti MC, Caponnetto F, Codrich M, Stefanizzi D, Fabris M, Sozio E, D'Aurizio F, Pucillo CEM, Sechi LA, **Tascini C,** Curcio F, Foresti GL, Piciarelli C, De Nardin A, Tell G, Isola M. Combining Deep Phenotyping of Serum Proteomics and Clinical Data via Machine Learning for COVID-19 Biomarker Discovery. Int J Mol Sci. 2022 Aug 15;23(16):9161. doi: 10.3390/ijms23169161. PMID: 36012423; PMCID: PMC9409308.
269. Sozio E, Moore NA, Fabris M, Ripoli A, Rumbolo F, Minieri M, Boverio R, Rodríguez Mulero MD, Lainez-Martinez S, Martínez Martínez M, Calvo D, Gregoriano C, Williams R, Brazzi L, Terrinoni A, Callegari T, Hernández Olivo M, Esteban-Torrella P, Calcerrada I, Bernasconi L, Kidd SP, Sbrana F, Miguens I, Gordon K, Visentini D, Legramante JM, Bassi F, Cortes N, Montrucchio G, Di Lecce VN, Lauritano EC, García de Guadiana-Romualdo L, González Del Castillo J, Bernal-Morell E, Andaluz-Ojeda D, Schuetz P, Curcio F, **Tascini C**, Saeed K. Identification of COVID-19 patients at risk of hospital admission and mortality: a European multicentre retrospective analysis of mid-regional pro-adrenomedullin. Respir Res. 2022 Aug 28;23(1):221. doi: 10.1186/s12931-022-02151-1. PMID: 36031619; PMCID: PMC9420187.
270. Da Porto A, **Tascini C,** Colussi G, Peghin M, Graziano E, De Carlo C, Bulfone L, Antonello M, Sozio E, Fabris M, Curcio F, Pucillo C, Catena C, Sechi LA. Relationship between cytokine release and stress hyperglycemia in patients hospitalized with COVID-19 infection. Front Med (Lausanne). 2022 Aug 19;9:988686. doi: 10.3389/fmed.2022.988686. PMID: 36059840; PMCID: PMC9437426.
271. **Tascini C**, Geminiani M, Sbrana F, Pagotto A, Martini L. Possible tattoo-transmitted monkeypox viral infection. Intern Emerg Med. 2022 Nov;17(8):2421-2422. doi: 10.1007/s11739-022-03090-x. Epub 2022 Sep 16. PMID: 36112319; PMCID: PMC9652165.
272. Palese A, Chiappinotto S, Peghin M, Marin M, Turello D, Caporale D, **Tascini C**. What Kind of Interventions Were Perceived as Effective Against Coronavirus-19 in Nursing Homes in Italy? A Descriptive Qualitative Study. Risk Manag Healthc Policy. 2022 Sep 21;15:1795-1808. doi: 10.2147/RMHP.S377249. PMID: 36171870; PMCID: PMC9510694.
273. Graziano E, Peghin M, De Martino M, De Carlo C, Da Porto A, Bulfone L, Casarsa V, Sozio E, Fabris M, Cifù A, Grassi B, Curcio F, Isola M, Sechi LA, **Tascini C**; GIRA-COVID study group. The impact of body composition on mortality of COVID-19 hospitalized patients: A prospective study on abdominal fat, obesity paradox and sarcopenia. Clin Nutr ESPEN. 2022 Oct;51:437-444. doi: 10.1016/j.clnesp.2022.07.003. Epub 2022 Jul 19. PMID: 36184240; PMCID: PMC9295328.
274. Peghin M, Bontempo G, De Martino M, Palese A, Gerussi V, Graziano E, Fabris M, D'Aurizio F, Sbrana F, Ripoli A, Curcio F, Isola M, **Tascini C.** Evaluation of qualitative and semi-quantitative cut offs for rapid diagnostic lateral flow test in relation to serology for the detection of SARS-CoV-2 antibodies: findings of a prospective study. BMC Infect Dis. 2022 Oct 31;22(1):810. doi: 10.1186/s12879-022-07786-5. PMID: 36316641; PMCID: PMC9619007.
275. Peghin M, Bontempo G, De Martino M, Palese A, Gerussi V, Graziano E, Fabris M, D'Aurizio F, Sbrana F, Ripoli A, Curcio F, Isola M, **Tascini C.** Evaluation of qualitative and semi-quantitative cut offs for rapid diagnostic lateral flow test in relation to serology for the detection of SARS-CoV-2 antibodies: findings of a prospective study. BMC Infect Dis. 2022 Oct 31;22(1):810. doi: 10.1186/s12879-022-07786-5. PMID: 36316641; PMCID: PMC9619007.
276. Mazzaferri F, Mirandola M, Savoldi A, De Nardo P, Morra M, Tebon M, Armellini M, De Luca G, Calandrino L, Sasset L, D'Elia D, Sozio E, Danese E, Gibellini D, Monne I, Scroccaro G, Magrini N, Cattelan A, **Tascini C**; MANTICO Working Group; Tacconelli E. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern. Elife. 2022 Nov 22;11:e79639. doi: 10.7554/eLife.79639. PMID: 36413383; PMCID: PMC9681201.
277. Pai MP, Cojutti PG, Gerussi V, Della Siega P, **Tascini C**, Pea F. Linezolid Population Pharmacokinetics to Improve Dosing in Cardiosurgical Patients: Factoring a New Drug-Drug Interaction Pathway. Clin Infect Dis. 2022 Nov 25:ciac917. doi: 10.1093/cid/ciac917. Epub ahead of print. PMID: 36424854.
278. Meini S, Bracalente I, Bontempo G, Longo B, De Martino M, **Tascini C**. Early 3-day course of remdesivir to prevent progression to severe Covid-19 in high-risk patients with hospital-acquired SARS-CoV-2 infection: preliminary results from two Italian outbreaks. New Microbiol. 2022 Dec;45(4):304-307. PMID: 36538294.
279. Vetrugno L, Castaldo N, Fantin A, Deana C, Cortegiani A, Longhini F, Forfori F, Cammarota G, Grieco DL, Isola M, Navalesi P, Maggiore SM, Bassetti M, Chetta A, Confalonieri M, De Martino M, Ferrari G, Francisi D, Luzzati R, Meini S, Scozzafava M, Sozio E, **Tascini C**, Bassi F, Patruno V; Italian COVI-MIX Study Group; De Robertis E, Aldieri C, Ball L, Baratella E, Bartoletti M, Boscolo A, Burgazzi B, Catalanotti V, Confalonieri P, Corcione S, De Rosa FG, De Simoni A, Bono VD, Tria RD, Forlani S, Giacobbe DR, Granozzi B, Labate L, Lococo S, Lupia T, Matellon C, Mehrabi S, Morosi S, Mongodi S, Mura M, Nava S, Pol R, Pettenuzzo T, Quyen NH, Rescigno C, Righi E, Ruaro B, Salton F, Scabini S, Scarda A, Sibani M, Tacconelli E, Tartaglione G, Tazza B, Vania E, Viale P, Vianello A, Visentin A, Zuccon U, Meroi F, Buonsenso D. Ventilatory associated barotrauma in COVID-19 patients: A multicenter observational case control study (COVI-MIX-study). Pulmonology. 2022 Nov 24:S2531-0437(22)00260-4. doi: 10.1016/j.pulmoe.2022.11.002. Epub ahead of print. PMID: 36669936; PMCID: PMC9684110.
280. Palese A, Visintini E, Bressan V, Fonda F, Chiappinotto S, Grassetti L, Peghin M, **Tascini C**, Balestrieri M, Colizzi M. Using Metaphors to Understand Suffering in COVID-19 Survivors: A Two Time-Point Observational Follow-Up Study. Int J Environ Res Public Health. 2023 Jan 12;20(2):1390. doi: 10.3390/ijerph20021390. PMID: 36674143; PMCID: PMC9859410.
281. Pizzano U, Facchin G, Marcon C, Fabris M, Battista ML, Cerno M, Geromin A, Pucillo M, Petruzzellis G, Vianello G, Battaglia G, Peressutti R, Grillone L, **Tascini C**, Curcio F, Fanin R, Patriarca F. Antibody, cell-mediated response and infection susceptibility in allogeneic hematopoietic stem cell recipients after COVID-19 mRNA vaccination. Transpl Infect Dis. 2023 Feb 7:e14003. doi: 10.1111/tid.14003. Epub ahead of print. PMID: 36748718.
282. D'arminio Monforte A, Tavelli A, Sala M, Mondi A, Rusconi S, Antinori S, Puoti M, Celesia BM, Taramasso L, Saracino A, Antinori A, Cozzi-Lepri A; ICONA Foundation Study Group. Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study. J Antimicrob Chemother. 2023 Feb 13:dkad026. doi: 10.1093/jac/dkad026. Epub ahead of print. PMID: 36775983.

Attività di ricerca

[MK-4482-002](https://asufc.sanita.fvg.it/it/sperimentazioni-cliniche/profit/mk-4482-002.html)

Studio clinico di Fase II/III, randomizzato, controllato con placebo, in doppio cieco per valutare l'efficacia, la sicurezza e la farmacocinetica di MK-4482 in partecipanti adulti non ospedalizzati con COVID-19.

sperimentatore principale: Dott. Carlo Tascini

BPR-CS-009

Studio randomizzato, in doppio cieco e multicentrico volto a stabilire l’efficacia e la sicurezza di ceftobiprolo medocaril rispetto a daptomicina nel trattamento della batterimia sostenuta da Staphylococcus aureus, endocardite infettiva compresa.

sperimentatore principale: Dott. Carlo Tascini

[ELDERLY COVID-19 FVG 1](https://asufc.sanita.fvg.it/it/sperimentazioni-cliniche/no-profit/elderly-covid-19-fvg1.html)

Caratteristiche cliniche ed epidemiologiche delle infezioni da SARS-CoV-2 nelle strutture residenziali per anziani (ELDERLY COVID-19 FVG1)

sperimentatore principale: Dott. Carlo Tascini

[ELDERLY COVID 19 FVG 2](https://asufc.sanita.fvg.it/it/sperimentazioni-cliniche/no-profit/elderly-covid-19-fvg2.html)

Caratteristiche immunologiche e monitoraggio clinico di soggetti con diagnosi confermata di COVID-19 nelle strutture residenziali per anziani. (ELDERLY COVID 19 FVG 2)

sperimentatore principale: Dott. Carlo Tascini

[CORMOR 4](https://asufc.sanita.fvg.it/it/sperimentazioni-cliniche/no-profit/cormor-4.html)

Utilizzo combinato di test sierologici e monitoraggio clinico di soggetti con diagnosi confermata di COVID 19. (CORMOR 4)

sperimentatore principale: Dott. Carlo Tascini

[C2661041](https://asufc.sanita.fvg.it/it/sperimentazioni-cliniche/profit/c2661041.html)

Studio retrospettivo multinazionale di revisione delle cartelle cliniche per valutare le caratteristiche, gli esiti del trattamento e l'utilizzo delle risorse fra pazienti adulti ricoverati in ospedale per polmonite acquisita in comunità (CAP-Community-acquired pneumonia) o infezioni di cute e tessuti molli complicate (CSSTI, Complicated Skin and Soft Tissue iIfections) trattate con Zinforo®. (C2661041)

sperimentatore principale: Dott. Carlo Tascini

[DALBADIA](https://asufc.sanita.fvg.it/it/sperimentazioni-cliniche/profit/dalbadia.html)

Studio osservazionale retrospettivo sull'utilizzo nella normale pratica clinica di dalbavancina in pazienti diabetici affetti da infezioni.

sperimentatore principale: Dott. Carlo Tascini

[FORTRESS](https://asufc.sanita.fvg.it/it/sperimentazioni-cliniche/profit/fortress.html)

Registro clinico europeo, prospettico, multicentrico, non interventistico, non comparativo per valutare l'esito clinico e la sicurezza del trattamento di pazienti gravemente infetti con Fosfomicina i.v FORTRESS.

sperimentatore principale: Dott. Carlo Tascini

[MANTICO](https://asufc.sanita.fvg.it/it/sperimentazioni-cliniche/no-profit/mantico.html)

Studio clinico adattativo, randoMizzato, controllato con placebo, sull’uso di ANTIcorpi monoclonali nei pazienti affetti da forma lieve-moderata di COvid-19. (MANTICO)

sperimentatore principale: Dott. Carlo Tascini

Partecipazioni a Comitati scientifici

Membro attivo del Consiglio Direttivo di SITA – Società Italiana di Terapia Antinfettiva

Membro attivo SIMIT – Società Italiana di Malattie Infettive e Tropicali

Membro attivo ESCMID – European Society of Clinical Microbiology and Infectious Diseases

Convegni

2022

1. Fad a distanza SIAARTI: The burden and origins of co-infections and superinfections in
2. complicated patients with long ICU stay and immune dysfunction. Relatore: Epidemiology and management of sCAP
3. Webinar Infezioni gravi da gram negativi, 20 gennaio 2022, Relatore: Sepsi nel paziente con trapianto da organo solido.
4. Webinar Infezioni gravi da gram negativi, 16 febbraio 2022, Relatore: Sepsi nel paziente con trapianto da organo solido.
5. Webinar Infezioni gravi da gram negativi, 17 marzo 2022, Relatore: Sepsi nel paziente con trapianto da organo solido.
6. Congresso Nazionale SIA (Società Italiana di Andrologia, le prostatiti nell’univeso andrologico. Roma 8-9 aprile 2022, relatore: La terapia antibiotica nelle infezioni prostatiche: quando e come.
7. 7th INFECTO, Infettivologia del terzo millennio, cosa c’è dopo il COVID-19. Paestum (SA) 5-6 maggio 2022. Relatore: Chi deve prescrivere gli antibiotici in terapia intensiva: un intensivista o un infettivologo?”
8. Live webinar, VACCINAZIONE ANTIPNEUMOCOCCICANEL PAZIENTE ADULTO E A RISCHIO, 12 maggio 2022. Relatore: Lo pneumococco: epidemiologia e nuovi sierotipi emergenti
9. Web conference Idea Funghi IFI nei pazienti ematologici 22 maggio 2021. Relatore: IFI NEI PAZIENTI EMATOLOGICI: Update e approfondimenti.
10. Virtual Expert meeting triveneto, Identification, 31 maggio 2022, Relatore: Gestione attuale del paziente sottoposto a HSCT allogenico e infezioni fungine, il punto di vista dell’infettivologo.
11. XVI Congresso regionale SIMEU Campania, le emergenze dimenticate, Napoli 7-8 giugno 2022. Relatore: Nuove strategie antibiotiche per le infezioni difficili.

2023

1. XVI Convegno Nazionale IBAT 2023 Infezioni Batteriche micotiche, virali e parassitarie Attualità Terapeutiche Napoli, 26-28 gennaio 2023 Relatore: Infezioni da *A. baumannii* MDR.
2. INFECTI ON TOP INFEZIONI IN PRIMO PIANO ROMA 1 FEBBRAIO 2023 Partecipante alla TAVOLA ROTONDA – Confronto tra esperti: malattie infettive e strategie per il futuro.
3. HTIDE Hot Topics in Infectious Diseases Burning issues on the management of Infectious Disease February 2nd 2023 WEBINAR LIVE Partecipant Round Table – The world of Amtimicrobial stewardship in 2022.
4. Women and research during pandemics a great èast and a more exciting future Udine 08/03/2023 Moderatore: Facing the ever-emerging pandemic: are there any new drugs?
5. TEAM Training Experience in AntiMicrobials Appropriatezza terapeutica nell’attuale contest infettivologico Vicenza 16 marzo 2023 Relatore: Appropriatezza terapeutica e Antimicrobial Stewardship.
6. Congresso: Il trapianto di cellule staminali emopoietiche e le terapie cellulari in FVG oggi Udine, 17 marzo 2023 Moderatore: Strategie per ottimizzare trapianto e CAR-T: i percorsi.
7. Draft Summit: Controversie e Consensi nel ruolo dei mAbs nell’Early Treatment del paziente fragile con COVID-19: non creiamo anticorpi -> Location Roma (22 - 23 Marzo 2023) Relatore: Identikit del paziente elegibile a EarlyTreatment con mAbs e AVs: facciamo chiarezza.
8. Summit mAbs nell’Early Treatment Controversie e consensi nel paziente fragile con COVID-19: non creiamo anticorpi Roma, 22-23 marzo 2023 Relatore: Identikit del paziente eleggibile a Early Treatment con mAbs e AVs: facciamo chiarezza.
9. TEAM Training Experience in AntiMicrobials Appropriatezza terapeutica nell’attuale contest infettivologico Belluno 23 marzo 2023 Relatore: Appropriatezza terapeutica e Antimicrobial Stewardship.
10. ECCMID 2023 Patients with most critical acute bacterial skin infections: which patients, ho to identify and how to best manage? April 15th, Copenaghen Relatore:  Identifying challenging patients: clinical cases to guide treatment approach. Transforming care of the patients with acute bacteria skin infections: Patient cases: oritavancin Patient cases: delafloxacin.
11. DISCOVER Profilassi, trattamento e follow up dell’infezione da SARS-CoV-2 nel paziente fragile 28 aprile 2023 relatore: Dalla valutazione del paziente all’algoritmo decisionale.
12. DISCOVER Profilassi, trattamento e follow up dell’infezione da SARS-CoV-2 nel paziente fragile 28 aprile 2023/12 dicembre 2023 Online sulla piattaforma <https://fad.academy-congressi.it> **28 04 2023** WEBINAR 1 | Dalla selezione al follow-up del paziente esposto all’infezione da SARS-CoV-2 **23 05 2023**WEBINAR 2 | Paziente oncoematologico **20 06 2023**WEBINAR 3 | Paziente trapiantato di cellule staminali emopoietiche **18 07 2023** WEBINAR 4 | Paziente immunocompromesso con deplezione dei linfociti B **19 09 2023** WEBINAR 5 | Paziente trapiantato di organo solido **16 10 2023** WEBINAR 6 | Paziente immunodeficiente **21 11 2023** WEBINAR 7 | Paziente oncologico **12 12 2023** WEBINAR 8 | I percorsi di cura e i modelli organizzativi.
13. Convegno FOCUS SU TERAPIE DI SUPPORTO 2023 BOLOGNA, 8 MAGGIO 2023 Relatore: Nuovi antibiotici e nuove resistenze.
14. INFEZIONI GRAVI DA GRAM NEGATIVI Strategie di diagnosi e trattamento del paziente critico e immunodepresso FAD SINCRONA <https://fad.academy-congressi.it> 16 maggio 2023 Relatore: Paziente ematologico.
15. I biomarcatori per ottimizzare la gestione del paziente. Webinar SIMEUP – 30 maggio 2023 Relatore: Ruolo e razionale d’uso dei biomarcatori d’infezione nel giovane adulto.
16. Relatore in modalità virtuale al progetto: “ANTInfectives Showcase: Ceftazidina/Avibactam: il place in therapy nelle infezioni da Gram – MDR” 06 giugno 2023.
17. Corso Ecm Residenziale + FAD Sincrona III SICILIA WORKSHOP ON ANTIMICROBIAL THERAPY 09 giugno 2023 Hotel Palermo Sede dell’evento Residenziale Relatore: Modelli organizzativi e profilassi con monoclonali.
18. INFEZIONI GRAVI DA GRAM NEGATIVI Strategie di diagnosi e trattamento del paziente critico e immunodepresso FAD SINCRONA <https://fad.academy-congressi.it> 12 giugno 2023 Relatore: Paziente ematologico.
19. Getione delle infezioni non complicate del basso tratto urinario Trento 17 giugno 2023 Relatore: Il trattamento delle infezioni delle vie urinarie: il punto di vista dell’infettivologo.
20. Early treatment for COVID-19 Aspetti clinici e gestionali del paziente complesso con COVID -19 Padova, 19 giugno 2023 Relatore: La dimensione del paziente fragile elegibile all’early treatment (aging, fragile, vulnerabile) Sliding doors: il farmaco giusto al paziente giusto: profili dei pazienti candidati agli antivirali e agli anticorpi Razionali di scelte terapeutica nel paziente fragile con early treatment: Aspetti virologici Aspetti farmacologici Evidenze cliniche (trials e real world evidence) Pazienti vulnerabili, dalla teoria alla pratica Esperienze esemplificative di pratica clinica quotidiana Visione e commento del documento realizzato dal real time Scribing.
21. Il Puzzle dell'antibioticoterapia LA GESTIONE TERAPEUTICA DELL'ELEVATA COMPLESSITA': BUGS AND SITES Bologna, 20-21 Giugno 2023 Relatore: MRSA.

Autorizzo il trattamento dei miei dati personali ai sensi dell’art. 13 D. Lgs. 30 giugno 2003 n°196 – “Codice in materia di protezione dei dati personali” e dell’art. 13 GDPR 679/16 – “Regolamento europeo sulla protezione dei dati personali"

Data, 26 giugno 2023